AU2013200528B2 - Inhibitors of C-FMS kinase - Google Patents
Inhibitors of C-FMS kinase Download PDFInfo
- Publication number
- AU2013200528B2 AU2013200528B2 AU2013200528A AU2013200528A AU2013200528B2 AU 2013200528 B2 AU2013200528 B2 AU 2013200528B2 AU 2013200528 A AU2013200528 A AU 2013200528A AU 2013200528 A AU2013200528 A AU 2013200528A AU 2013200528 B2 AU2013200528 B2 AU 2013200528B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- formula
- compounds
- ora
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003112 inhibitor Substances 0.000 title description 7
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 title description 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 219
- 238000000034 method Methods 0.000 claims abstract description 95
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 33
- 239000012453 solvate Substances 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 18
- 206010027476 Metastases Diseases 0.000 claims abstract description 15
- 230000009401 metastasis Effects 0.000 claims abstract description 15
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 9
- 208000037408 Device failure Diseases 0.000 claims abstract description 8
- 208000037099 Prosthesis Failure Diseases 0.000 claims abstract description 8
- 206010003246 arthritis Diseases 0.000 claims abstract description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 7
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 7
- 208000006386 Bone Resorption Diseases 0.000 claims abstract description 6
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 6
- 208000002193 Pain Diseases 0.000 claims abstract description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 6
- 206010039491 Sarcoma Diseases 0.000 claims abstract description 6
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 6
- 230000024279 bone resorption Effects 0.000 claims abstract description 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims abstract description 6
- 230000000010 osteolytic effect Effects 0.000 claims abstract description 6
- 230000036407 pain Effects 0.000 claims abstract description 6
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 5
- 208000010191 Osteitis Deformans Diseases 0.000 claims abstract description 5
- 208000027868 Paget disease Diseases 0.000 claims abstract description 5
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 5
- 208000027202 mammary Paget disease Diseases 0.000 claims abstract description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims abstract description 4
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 4
- 201000009277 hairy cell leukemia Diseases 0.000 claims abstract description 4
- 201000005202 lung cancer Diseases 0.000 claims abstract description 4
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 4
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 4
- 206010046766 uterine cancer Diseases 0.000 claims abstract description 4
- 206010006002 Bone pain Diseases 0.000 claims abstract description 3
- 206010065390 Inflammatory pain Diseases 0.000 claims abstract description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 3
- 208000004296 neuralgia Diseases 0.000 claims abstract description 3
- 230000009278 visceral effect Effects 0.000 claims abstract description 3
- 208000009935 visceral pain Diseases 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 172
- -1 -ORa Chemical group 0.000 claims description 106
- 229910052739 hydrogen Inorganic materials 0.000 claims description 42
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 30
- 229910052799 carbon Inorganic materials 0.000 claims description 29
- 125000000623 heterocyclic group Chemical class 0.000 claims description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 13
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 125000002883 imidazolyl group Chemical group 0.000 claims description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 125000003386 piperidinyl group Chemical group 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 9
- 125000000392 cycloalkenyl group Chemical class 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 125000002541 furyl group Chemical group 0.000 claims description 7
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000000335 thiazolyl group Chemical group 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 241000689227 Cora <basidiomycete fungus> Species 0.000 claims description 6
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 208000037803 restenosis Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000031886 HIV Infections Diseases 0.000 claims description 2
- 208000037357 HIV infectious disease Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000011623 Obstructive Lung disease Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 claims 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract description 17
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract description 17
- 150000004677 hydrates Chemical class 0.000 abstract description 9
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 7
- 102000020233 phosphotransferase Human genes 0.000 abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 50
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 48
- 239000003153 chemical reaction reagent Substances 0.000 description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 40
- 238000006243 chemical reaction Methods 0.000 description 39
- 239000000203 mixture Substances 0.000 description 37
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- 239000000243 solution Substances 0.000 description 29
- 239000002904 solvent Substances 0.000 description 27
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 26
- 239000002253 acid Substances 0.000 description 25
- 235000019439 ethyl acetate Nutrition 0.000 description 25
- 238000001819 mass spectrum Methods 0.000 description 23
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 22
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 21
- 125000004093 cyano group Chemical group *C#N 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
- 239000011734 sodium Substances 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 150000002148 esters Chemical class 0.000 description 18
- 230000009467 reduction Effects 0.000 description 18
- 238000006722 reduction reaction Methods 0.000 description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- XTDRPNJABDWQFI-UHFFFAOYSA-N 5-cyano-1h-imidazole-2-carboxylic acid Chemical compound OC(=O)C1=NC(C#N)=CN1 XTDRPNJABDWQFI-UHFFFAOYSA-N 0.000 description 15
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 15
- 239000000543 intermediate Substances 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- 238000005859 coupling reaction Methods 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 238000007254 oxidation reaction Methods 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 150000001408 amides Chemical class 0.000 description 9
- 230000008878 coupling Effects 0.000 description 9
- 238000010168 coupling process Methods 0.000 description 9
- 238000005658 halogenation reaction Methods 0.000 description 9
- 230000003647 oxidation Effects 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000006069 Suzuki reaction reaction Methods 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 8
- 150000002460 imidazoles Chemical class 0.000 description 8
- 150000002576 ketones Chemical class 0.000 description 8
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000012267 brine Substances 0.000 description 7
- 230000031709 bromination Effects 0.000 description 7
- 238000005893 bromination reaction Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000026030 halogenation Effects 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 150000001336 alkenes Chemical class 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 229910052744 lithium Inorganic materials 0.000 description 6
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 6
- 229910000000 metal hydroxide Inorganic materials 0.000 description 6
- 150000004692 metal hydroxides Chemical class 0.000 description 6
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 6
- 150000003457 sulfones Chemical class 0.000 description 6
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000012131 assay buffer Substances 0.000 description 5
- 125000005620 boronic acid group Chemical class 0.000 description 5
- 125000001246 bromo group Chemical group Br* 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000010931 ester hydrolysis Methods 0.000 description 5
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 150000003335 secondary amines Chemical class 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 150000003462 sulfoxides Chemical class 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000010189 synthetic method Methods 0.000 description 5
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 5
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 5
- MYGIJNBCRDCCNV-UHFFFAOYSA-N 1-[4-amino-3-(4,4-dimethylcyclohexen-1-yl)phenyl]cyclopropane-1-carbonitrile Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(C=2)C2(CC2)C#N)N)=C1 MYGIJNBCRDCCNV-UHFFFAOYSA-N 0.000 description 4
- KYWMCFOWDYFYLV-UHFFFAOYSA-N 1h-imidazole-2-carboxylic acid Chemical class OC(=O)C1=NC=CN1 KYWMCFOWDYFYLV-UHFFFAOYSA-N 0.000 description 4
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- OQHKEVATSGWALO-UHFFFAOYSA-N 4-bromo-2-(4,4-dimethylcyclohexen-1-yl)aniline Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(Br)C=2)N)=C1 OQHKEVATSGWALO-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical class OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 4
- SHQSVMDWKBRBGB-UHFFFAOYSA-N cyclobutanone Chemical compound O=C1CCC1 SHQSVMDWKBRBGB-UHFFFAOYSA-N 0.000 description 4
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
- 229960001484 edetic acid Drugs 0.000 description 4
- 239000012039 electrophile Substances 0.000 description 4
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 4
- 238000002875 fluorescence polarization Methods 0.000 description 4
- 150000002367 halogens Chemical group 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 125000003003 spiro group Chemical group 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- GPASEBZMAVEREE-UHFFFAOYSA-N 6-bromo-2-(4,4-dimethylcyclohexen-1-yl)pyridin-3-amine Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(Br)N=2)N)=C1 GPASEBZMAVEREE-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000002841 Lewis acid Substances 0.000 description 3
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 3
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 3
- 238000006619 Stille reaction Methods 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 239000012445 acidic reagent Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- 150000007517 lewis acids Chemical class 0.000 description 3
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- HWFBGGLUEZIDOE-UHFFFAOYSA-N (4,4-dimethylcyclohexen-1-yl)boronic acid Chemical compound CC1(C)CCC(B(O)O)=CC1 HWFBGGLUEZIDOE-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- KHKYPEQSHDYAKO-UHFFFAOYSA-N 1-(4-amino-3-bromophenyl)cyclohexane-1-carbonitrile Chemical compound C1=C(Br)C(N)=CC=C1C1(C#N)CCCCC1 KHKYPEQSHDYAKO-UHFFFAOYSA-N 0.000 description 2
- FFZZJHSYVGWSHQ-UHFFFAOYSA-N 1-(4-amino-3-bromophenyl)cyclopropane-1-carbonitrile Chemical compound C1=C(Br)C(N)=CC=C1C1(C#N)CC1 FFZZJHSYVGWSHQ-UHFFFAOYSA-N 0.000 description 2
- JTMAWZMLYUMWKL-UHFFFAOYSA-N 1-(4-aminophenyl)cyclopropane-1-carbonitrile Chemical compound C1=CC(N)=CC=C1C1(C#N)CC1 JTMAWZMLYUMWKL-UHFFFAOYSA-N 0.000 description 2
- SPJWHGODDUYDNH-UHFFFAOYSA-N 1-(4-nitrophenyl)cyclohexane-1-carbonitrile Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1(C#N)CCCCC1 SPJWHGODDUYDNH-UHFFFAOYSA-N 0.000 description 2
- QDCPXRWNBXWBPZ-UHFFFAOYSA-N 1-(4-nitrophenyl)cyclopentane-1-carboxylic acid Chemical compound C=1C=C([N+]([O-])=O)C=CC=1C1(C(=O)O)CCCC1 QDCPXRWNBXWBPZ-UHFFFAOYSA-N 0.000 description 2
- HPXZSOJJLOBJPW-UHFFFAOYSA-N 1-[4-amino-3-(4,4-dimethylcyclohexen-1-yl)phenyl]cyclohexane-1-carbonitrile Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(C=2)C2(CCCCC2)C#N)N)=C1 HPXZSOJJLOBJPW-UHFFFAOYSA-N 0.000 description 2
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical group C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- NWVGXXPWOYZODV-UHFFFAOYSA-N 1h-imidazole-5-carbonitrile Chemical compound N#CC1=CN=CN1 NWVGXXPWOYZODV-UHFFFAOYSA-N 0.000 description 2
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- QASWBVDBXRETQW-UHFFFAOYSA-N 4-[4-amino-3-(4,4-dimethylcyclohexen-1-yl)phenyl]cyclohexan-1-one Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(C=2)C2CCC(=O)CC2)N)=C1 QASWBVDBXRETQW-UHFFFAOYSA-N 0.000 description 2
- XQSZENOTKVEPEU-UHFFFAOYSA-N 4-morpholin-4-ylcyclohexan-1-one Chemical compound C1CC(=O)CCC1N1CCOCC1 XQSZENOTKVEPEU-UHFFFAOYSA-N 0.000 description 2
- BPMBNLJJRKCCRT-UHFFFAOYSA-N 4-phenylbenzonitrile Chemical compound C1=CC(C#N)=CC=C1C1=CC=CC=C1 BPMBNLJJRKCCRT-UHFFFAOYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- OTLJWGCPQDJSBN-UHFFFAOYSA-N 5-cyano-n-[2-(4,4-dimethylcyclohexen-1-yl)-4-(1-hydroxy-4,4-dimethoxycyclohexyl)phenyl]-1h-imidazole-2-carboxamide Chemical compound C1CC(OC)(OC)CCC1(O)C(C=C1C=2CCC(C)(C)CC=2)=CC=C1NC(=O)C1=NC=C(C#N)N1 OTLJWGCPQDJSBN-UHFFFAOYSA-N 0.000 description 2
- UZVBAENLXVNXCL-UHFFFAOYSA-N 6-bromo-2-iodopyridin-3-amine Chemical compound NC1=CC=C(Br)N=C1I UZVBAENLXVNXCL-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 229910013063 LiBF 4 Inorganic materials 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 2
- 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 238000010976 amide bond formation reaction Methods 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 150000001768 cations Chemical group 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000006352 cycloaddition reaction Methods 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 230000005595 deprotonation Effects 0.000 description 2
- 238000010537 deprotonation reaction Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- VDDXQSUSMHZCLS-UHFFFAOYSA-N ethenyl trifluoromethanesulfonate Chemical class FC(F)(F)S(=O)(=O)OC=C VDDXQSUSMHZCLS-UHFFFAOYSA-N 0.000 description 2
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical group Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 2
- MSMGXWFHBSCQFB-UHFFFAOYSA-N ethyl cyanoformate Chemical compound CCOC(=O)C#N MSMGXWFHBSCQFB-UHFFFAOYSA-N 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 2
- WUEVEAZIMNIMQX-UHFFFAOYSA-N n-[4-bromo-2-(4,4-dimethylcyclohexen-1-yl)phenyl]-5-cyano-1h-imidazole-2-carboxamide Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(Br)C=2)NC(=O)C=2NC=C(N=2)C#N)=C1 WUEVEAZIMNIMQX-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 125000001979 organolithium group Chemical group 0.000 description 2
- 125000002734 organomagnesium group Chemical group 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- BNQGKHUEVQWESM-UHFFFAOYSA-M potassium;4-cyano-1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxylate Chemical compound [K+].C[Si](C)(C)CCOCN1C=C(C#N)N=C1C([O-])=O BNQGKHUEVQWESM-UHFFFAOYSA-M 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 101150114085 soc-2 gene Proteins 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- AGPLUQQOKHTNQG-UHFFFAOYSA-N tert-butyl 1-(4-nitrophenyl)cyclopentane-1-carboxylate Chemical compound C=1C=C([N+]([O-])=O)C=CC=1C1(C(=O)OC(C)(C)C)CCCC1 AGPLUQQOKHTNQG-UHFFFAOYSA-N 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
- VKRKCBWIVLSRBJ-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-8-one Chemical compound C1CC(=O)CCC21OCCO2 VKRKCBWIVLSRBJ-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dithiothreitol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 1
- FIVQWANVHJBLAY-UHFFFAOYSA-N 1-(2-trimethylsilylethoxymethyl)imidazole-4-carbonitrile Chemical compound C[Si](C)(C)CCOCN1C=NC(C#N)=C1 FIVQWANVHJBLAY-UHFFFAOYSA-N 0.000 description 1
- JRIZOAJMALXNOO-UHFFFAOYSA-N 1-(4-aminophenyl)cyclohexane-1-carbonitrile Chemical compound C1=CC(N)=CC=C1C1(C#N)CCCCC1 JRIZOAJMALXNOO-UHFFFAOYSA-N 0.000 description 1
- ANLABNUUYWRCRP-UHFFFAOYSA-N 1-(4-nitrophenyl)cyclopentane-1-carbonitrile Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1(C#N)CCCC1 ANLABNUUYWRCRP-UHFFFAOYSA-N 0.000 description 1
- YUHRZXOPOFLZEV-UHFFFAOYSA-N 1-(4-nitrophenyl)cyclopropane-1-carbonitrile Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1(C#N)CC1 YUHRZXOPOFLZEV-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- QXXHHHWXFHPNOS-UHFFFAOYSA-N 1-phenylcyclohexane-1-carboxylic acid Chemical compound C=1C=CC=CC=1C1(C(=O)O)CCCCC1 QXXHHHWXFHPNOS-UHFFFAOYSA-N 0.000 description 1
- QMQZIXCNLUPEIN-UHFFFAOYSA-N 1h-imidazole-2-carbonitrile Chemical class N#CC1=NC=CN1 QMQZIXCNLUPEIN-UHFFFAOYSA-N 0.000 description 1
- MJLDLTXVYLVTMP-UHFFFAOYSA-N 2-(4,4-dimethylcyclohexen-1-yl)-6-[1-(2-pyrrolidin-1-ylethoxy)cyclopentyl]pyridin-3-amine Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(N=2)C2(CCCC2)OCCN2CCCC2)N)=C1 MJLDLTXVYLVTMP-UHFFFAOYSA-N 0.000 description 1
- PXNJGLAVKOXITN-UHFFFAOYSA-N 2-(4-nitrophenyl)acetonitrile Chemical compound [O-][N+](=O)C1=CC=C(CC#N)C=C1 PXNJGLAVKOXITN-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- SVOCLWUDDWXHFW-UHFFFAOYSA-N 2-methylsulfanyl-1h-imidazole Chemical class CSC1=NC=CN1 SVOCLWUDDWXHFW-UHFFFAOYSA-N 0.000 description 1
- NTIGNJOEVBTPJJ-UHFFFAOYSA-N 3,3-dibromopentane Chemical compound CCC(Br)(Br)CC NTIGNJOEVBTPJJ-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- UOJCLZFJKRTXGV-UHFFFAOYSA-N 4,4-dimethoxycyclohexan-1-one Chemical compound COC1(OC)CCC(=O)CC1 UOJCLZFJKRTXGV-UHFFFAOYSA-N 0.000 description 1
- QOKGZTDRQTUUSB-UHFFFAOYSA-N 4-(4-nitrophenyl)cyclohexan-1-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1CCC(=O)CC1 QOKGZTDRQTUUSB-UHFFFAOYSA-N 0.000 description 1
- HHTYEQWCHQEJNV-UHFFFAOYSA-N 4-bromo-2-iodoaniline Chemical compound NC1=CC=C(Br)C=C1I HHTYEQWCHQEJNV-UHFFFAOYSA-N 0.000 description 1
- SWKFGRZOLANOTI-UHFFFAOYSA-N 4-cyano-n-[4-(1-cyanocyclohexyl)-2-(4,4-dimethylcyclohexen-1-yl)phenyl]-1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxamide Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(C=2)C2(CCCCC2)C#N)NC(=O)C=2N(C=C(N=2)C#N)COCC[Si](C)(C)C)=C1 SWKFGRZOLANOTI-UHFFFAOYSA-N 0.000 description 1
- JLNMBIKJQAKQBH-UHFFFAOYSA-N 4-cyclohexylaniline Chemical compound C1=CC(N)=CC=C1C1CCCCC1 JLNMBIKJQAKQBH-UHFFFAOYSA-N 0.000 description 1
- YKAYMASDSHFOGI-UHFFFAOYSA-N 4-phenylcyclohexan-1-one Chemical compound C1CC(=O)CCC1C1=CC=CC=C1 YKAYMASDSHFOGI-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- LGYJKZIIDQSXGH-UHFFFAOYSA-N 5-cyano-n-[2-(4,4-dimethylcyclohexen-1-yl)-4-(1-hydroxycyclohexyl)phenyl]-1h-imidazole-2-carboxamide Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(C=2)C2(O)CCCCC2)NC(=O)C=2NC=C(N=2)C#N)=C1 LGYJKZIIDQSXGH-UHFFFAOYSA-N 0.000 description 1
- UUMTZTDBNOXQLG-UHFFFAOYSA-N 5-cyano-n-[2-(4,4-dimethylcyclohexen-1-yl)-4-(1-hydroxycyclopentyl)phenyl]-1h-imidazole-2-carboxamide Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(C=2)C2(O)CCCC2)NC(=O)C=2NC=C(N=2)C#N)=C1 UUMTZTDBNOXQLG-UHFFFAOYSA-N 0.000 description 1
- GVSDVIDQCNDSFQ-UHFFFAOYSA-N 5-cyano-n-[2-(4,4-dimethylcyclohexen-1-yl)-4-(4-oxocyclohexyl)phenyl]-1h-imidazole-2-carboxamide Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(C=2)C2CCC(=O)CC2)NC(=O)C=2NC=C(N=2)C#N)=C1 GVSDVIDQCNDSFQ-UHFFFAOYSA-N 0.000 description 1
- HKLXDHCASVVKNG-UHFFFAOYSA-N 5-cyano-n-[4-(4,4-dimethoxycyclohexyl)-2-(4,4-dimethylcyclohexen-1-yl)phenyl]-1h-imidazole-2-carboxamide Chemical compound C1CC(OC)(OC)CCC1C(C=C1C=2CCC(C)(C)CC=2)=CC=C1NC(=O)C1=NC=C(C#N)N1 HKLXDHCASVVKNG-UHFFFAOYSA-N 0.000 description 1
- XTHKRYHULUJQHN-UHFFFAOYSA-N 6-bromopyridin-3-amine Chemical compound NC1=CC=C(Br)N=C1 XTHKRYHULUJQHN-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 238000006969 Curtius rearrangement reaction Methods 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 101100481404 Danio rerio tie1 gene Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102000054300 EC 2.7.11.- Human genes 0.000 description 1
- 108700035490 EC 2.7.11.- Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 101000933374 Gallus gallus Brain-specific homeobox/POU domain protein 3 Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000916629 Mus musculus Macrophage colony-stimulating factor 1 Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 101100481406 Mus musculus Tie1 gene Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 241000872931 Myoporum sandwicense Species 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241001538234 Nala Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical class NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100037483 POU domain, class 6, transcription factor 1 Human genes 0.000 description 1
- 101710196406 POU domain, class 6, transcription factor 1 Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 238000003482 Pinner synthesis reaction Methods 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 238000006085 Schmidt reaction Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000006859 Swern oxidation reaction Methods 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- IGFQYBOPZJMNPU-UHFFFAOYSA-N cyano 1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxylate Chemical compound C[Si](C)(C)CCOCN1C=CN=C1C(=O)OC#N IGFQYBOPZJMNPU-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 108010011222 cyclo(Arg-Pro) Proteins 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- ZQWPRMPSCMSAJU-UHFFFAOYSA-N cyclohexanecarboxylic acid methyl ester Natural products COC(=O)C1CCCCC1 ZQWPRMPSCMSAJU-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- UHYNYIGCGVDBTC-UHFFFAOYSA-N ethyl 1h-imidazole-2-carboxylate Chemical compound CCOC(=O)C1=NC=CN1 UHYNYIGCGVDBTC-UHFFFAOYSA-N 0.000 description 1
- RQMDFPGLTPLVTH-UHFFFAOYSA-N ethyl 4-cyano-1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxylate Chemical compound CCOC(=O)C1=NC(C#N)=CN1COCC[Si](C)(C)C RQMDFPGLTPLVTH-UHFFFAOYSA-N 0.000 description 1
- ZXYAWONOWHSQRU-UHFFFAOYSA-N ethyl 4-oxocyclohexanecarboxylate Chemical compound CCOC(=O)C1CCC(=O)CC1 ZXYAWONOWHSQRU-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DOUHZFSGSXMPIE-UHFFFAOYSA-N hydroxidooxidosulfur(.) Chemical class [O]SO DOUHZFSGSXMPIE-UHFFFAOYSA-N 0.000 description 1
- 125000005191 hydroxyalkylamino group Chemical group 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- MHCFAGZWMAWTNR-UHFFFAOYSA-M lithium perchlorate Chemical compound [Li+].[O-]Cl(=O)(=O)=O MHCFAGZWMAWTNR-UHFFFAOYSA-M 0.000 description 1
- 229910001486 lithium perchlorate Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- RYEXTBOQKFUPOE-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].CC[CH2-] RYEXTBOQKFUPOE-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000006525 methoxy ethyl amino group Chemical group [H]N(*)C([H])([H])C([H])([H])OC([H])([H])[H] 0.000 description 1
- BLYKGTCYDJZLFB-UHFFFAOYSA-N methyl 4-oxocyclohexane-1-carboxylate Chemical compound COC(=O)C1CCC(=O)CC1 BLYKGTCYDJZLFB-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- NFPJKOYCCPDZJB-UHFFFAOYSA-N n-[6-bromo-2-(4,4-dimethylcyclohexen-1-yl)pyridin-3-yl]-5-cyano-1h-imidazole-2-carboxamide Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(Br)N=2)NC(=O)C=2NC(=CN=2)C#N)=C1 NFPJKOYCCPDZJB-UHFFFAOYSA-N 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- BMNDJWSIKZECMH-UHFFFAOYSA-N nitrosyl bromide Chemical compound BrN=O BMNDJWSIKZECMH-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical group 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- 150000008648 triflates Chemical class 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Abstract
The invention is directed to compounds of Formula (I): wherein Z,X,J,R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fmus kinase. Methods of treating autoimmune diseases; and disease with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula (I), are also provided.
Description
INHIBITORS OF C-FMS KINASE The present application is a divisional application of Australian Application No. 2007240443, which is incorporated in its entirety herein by reference. 5 CROSS REFERENCE TO RELATED APPLICATION This application claims priority from United States Provisional Application Serial No. 60/ 793,667, filed on April 20, 2006, the contents of which are hereby incorporated by reference in their entirety. 10 BACKGROUND OF THE INVENTION The invention relates to novel compounds that function as protein tyrosine kinase inhibitors. More particularly, the invention relates to novel compounds that function as inhibitors of c-fins kinase. 15 Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field. Protein kinase are enzymes that serve as key components of signal transduction pathways by catalyzing the transfer of the terminal phosphate from adenosine 5' 20 triphosphate (ATP) to the hydroxy group of tyrosine, shrine and threonine residues of proteins. As a consequence, protein kinase inhibitors and substrates are valuable tools for assessing the physiological consequences of protein kinase activation. The overexpression or inappropriate expression of normal or mutant protein kinases in mammals has been demonstrated to play significant roles in the development of many 25 diseases, including cancer and diabetes. Protein kinases can be divided into two classes: those which preferentially phosphorylate tyrosine residues (protein tyrosine kinases) and those which preferentially phosphorylate serine and/or threonine residues (protein serine/threonine kinases). Protein tyrosine kinases perform diverse functions ranging from stimulation of cell 30 growth and differentiation to arrest of cell proliferation. They can be classified as either receptor protein tyrosine kinases or intracellular protein tyrosine kinases. The receptor protein tyrosine kinases, which possess an extracellular ligand binding domain and an la intracellular catalytic domain with intrinsic tyrosine kinase activity, are distributed among 20 subfamilies. lb Receptor tyrosine kinases of the epidermal growth factor ("EGF") family, which includes HER-1, HER-2/neu and HER-3 receptors, contain an extracellular binding domain, a transmembrane domain and an intracellular cytoplasmic catalytic domain. Receptor binding leads to the initiation of multiple intracellular tyrosine kinase dependent 5 phosphorylation processes, which ultimately results in oncogene transcription. Breast, colorectal and prostate cancers have been linked to this family of receptors. Insulin receptor ("IR") and insulin-like growth factor I receptor ("IGF-IR") are structurally and functionally related but exert distinct biological effects. IGF-iR over expression has been associated with breast cancer. 10 Platelet derived growth factor ("PDGF") receptors mediate cellular responses that include proliferation, migration and survival and include PDGFR, the stem cell factor receptor (c-kit) and c-fins. These receptors have been linked to diseases such as atherosclerosis, fibrosis and proliferative vitreoretinopathy. Fibroblast growth factor ("FGR") receptors consist of four receptors which are 15 responsible for the production of blood vessels, for limb outgrowth, and for the growth and differentiation of numerous cell types. Vascular endothelial growth factor ("VEGF"), a potent mitogen of endothelial cells, is produced in elevated amounts by many tumors, including ovarian carcinomas. The known receptors for VEGF are designated as VEGFR-1 (Flt-1), VEGFR-2 (KDR), 20 VEGFR-3 (Flt-4). A related group of receptors, tie-1 and tie-2 kinases, have been identified in vascular endothelium and hematopoietic cells. VEGF receptors have been linked to vasculogenesis and angiogenesis. Intracellular protein tyrosine kinases are also known as non-receptor protein tyrosine kinases. Over 24 such kinases have been identified and have been classified into 25 11 subfamilies. The serine/threonine protein kinases, like the cellular protein tyrosine kinases, are predominantly intracellular. Diabetes, angiogenesis, psoriasis, restenosis, ocular diseases, schizophrenia, rheumatoid arthritis, cardiovascular disease and cancer are exemplary of pathogenic conditions that have been linked with abnormal protein tyrosine kinase activity. Thus, a 30 need exists for selective and potent small-molecule protein tyrosine kinase inhibitors. U.S. Patent Nos. 6,383,790; 6,346,625; 6,235,746; 6,100,254 and PCT International 2 -3 Applications WO 01/47897, WO 00/27820 and WO 02/068406 are indicative of recent attempts to synthesize such inhibitors. It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative. 5 SUMMARY OF THE INVENTION The invention relates to selective and potent protein tyrosine kinase inhibitors by including potent inhibitors of c-fins kinase. According to a first aspect, the present invention provides a method of treating a 0 disorder selected from inflammation, cancer, cardiovascular disease, diseases with an inflammatory component, pain, metastasis, and autoimmune diseases in a mammal comprising administering to the mammal a therapeutically effective amount of at least one compound of Formula I Z NH 5 x J R 2 I or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein: R 4 R 4 R 4 HN 4 HN \ HN HN Wis 7N R4 R NN , N-N - R4o , or R4 H 20 wherein each R 4 is independently H, F, Cl, Br, I, OH, OCH 3 , OCH 2
CH
3 , SC(1.
4 )alkyl, SOC(i.
4 )alkyl, SO 2 C(1.
4 )alkyl, -C(I3)alkyl, CO 2 R , CONRR, C-- CR9, or CN; wherein Rd is H, or -C(1.
3 )alkyl; Re is H, or -C(1.
3 )alkyl; 25 R is H, or -C(1.
3 )alkyl; and R9 is H, -CH 2 OH, or -CH 2
CH
2
OH;
- 3a
R
2 is cycloalkyl, spiro-substituted cycloalkenyl, heterocyclyl, spirosubstituted piperidinyl, thiophenyl, dihydrosulfonopyranyl, phenyl, furanyl, tetrahydropyridyl, or dihydropyranyl, any of which may be independently substituted with one or two of each of the following: chloro, fluoro, hydroxy, C(1.
3 )alkyl, and C(1.
4 )alkyl; 5 Z is H, F, or CH 3 ; J is CH, or N; Ri R R R R 1 RY R Xis Rz / Rz j Rz / Rz S:oN 10 S R7 RR or R Rz Rz R 0 wherein 1 12 12 R is -C(1.
4 )alkyl, -ORa, -CN, -NA A , -SO 2
CH
3 , -COORa, -CO 2
CH
3 , -CH 2 -NA A,
-CONAA
2 , -CH 2 ORa, -OC(1.
4 )alkylORa, -NHCH 2
CH
2
CO
2 Ra, -NHCH 2
CH
2 ORa -NRaCH 2
CH
2
NAA
2 , -OC(1.
4 )alkylNAA 2 , -OCH 2
CO
2 Ra, -CH 2
CO
2 Ra 12 12 12
-CH
2
CH
2
SO
2 C(1.
4 )alkyl, -SO 2
CH
2
CH
2 NA'A2, -SOCH 2
CH
2 NA A2, -SCH 2
CH
2 NA A, 5 -NHSO 2
CH
2
CH
2 NAA 2 , phenyl, imidazolyl, thiazolyl, 4H-[1,2,4]oxadiazol-5-onyl, 4H-pyrrolo[2,3-b]pyrazinyl, pyridinyl, [1,3,4]oxadiazolyl, 4H-[1,2,4]triazolyl, tetrazolyl, pyrazolyl, [1,3,5]triazinyl, or [1,3,4]thiadiazolyl; Rz and Ry are independently H or -C(1.
4 )alkyl, wherein both Rz may have either syn or 20 anti stereochemistry; alternatively both Rz in a syn relationship may be taken together to form -(CH 2 )n 1 -, where n is 2 or 3;
R
3 is H, C(1.
4 )alkyl, C(1.
3 )alkyl-CF 3 , CH 2
CH
2
NH
2 , CH 2
CH
2 ORa, -COCH 3 , CONH 2 , or
CO
2 Ra. 25 A' is H, -C(1.4)alkyl, or CH2CH2OR a. A2 is H, -C(1.
4 )alkyl, CORa, CH 2
CON(CH
3
)
2 , -CH 2
CH
2 ORa, -CH 2
CH
2 SC(1.
4 )alkyl,
-CH
2
CH
2 SOC(1.
4 )alkyl, or -CH 2
CH
2
SO
2 C(1.
4 )alkyl; - 3b alternatively, A' and A 2 may be taken together with their attached nitrogen to form a heterocyclic ring selected from the following: Ra Raa Ra Ra Ra Ra N-1- R bb_-N N- - -S N-1- O=-S N-1 a Ra O Raa Ra Ra Ra Ra ~ Ra f \N- - S NJ- ..- 1 Nz// ,and Ra wherein Ra is H or C(i.
4 )alkyl; 5 Raa is H or C(1.
4 )alkyl; and Rbb is H, -C(1.
4 )alkyl, -CH 2
CH
2 0CH 2
CH
2 0CH 3 , -CH 2
CO
2 H, -C(O)C(1.
4 )alkyl, or -CH 2 C(O)C(1.
4 )alkyl. According to a second aspect, the present invention provides a method of treating osteoporosis, 0 Paget's disease, or other diseases in which bone resorption mediates morbidity including rheumatoid arthritis or other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, or tumor metastasis to bone in a mammal, comprising administering to the mammal in need of such treatment a therapeutically effective amount of at least one compound of Z NH 15 X J R 2 I or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein: - 3c HN HN 4 N, 4R W is 1 R4 R4 N N-N , or N R ; H wherein each R 4 is independently H, F, Cl, Br, I, OH, OCH 3 , OCH 2
CH
3 , SC(1.
4 )alkyl,
SOC(
1
.
4 )alkyl, SO 2
C(
1
.
4 )alkyl, -C( 1
.
3 )alkyl, CO 2 R , CONR R, C- CRg, or CN; 5 wherein Rd is H, or -C(1.
3 )alkyl; Re is H, or -C(1.
3 )alkyl; R is H, or -C(1.
3 )alkyl; and RI is H, -CH 2 OH, or -CH 2
CH
2 OH; 0 R 2 is cycloalkyl, spiro-substituted cycloalkenyl, heterocyclyl, spirosubstituted piperidinyl, thiophenyl, dihydrosulfonopyranyl, phenyl, furanyl, tetrahydropyridyl, or dihydropyranyl, any of which may be independently substituted with one or two of each of the following: chloro, fluoro, hydroxy, C(I1 3 )alkyl, and C(I1 4 )alkyl; 5 Z is H, F, or CH 3 ; J is CH, or N; R' R R' R R' RY Ri Xis Rz Rz Rz Rz R RRz wherein R 1 is -C(1.
4 )alkyl, -ORa, -CN, -NA A 2 , -SO 2
CH
3 , -COORa, -CO 2
CH
3 , 20 -CH 2
-NAA
2 , -CONAA 2 , -CH 2 ORa, -OC(1.
4 )alkylORa, -NHCH 2
CH
2
CO
2 Ra,
-NHCH
2
CH
2 ORa, -NRaCH 2
CH
2 NAA 2, -OC(1.
4 )alkylNAA 2 , -OCH 2
CO
2 Ra, -CH 2
CO
2 Ra 12 12 12
-CH
2
CH
2
SO
2 C(I1 4 )alkyl, -SO 2
CH
2
CH
2 NA1A , -SOCH 2
CH
2 NA A , -SCH 2
CH
2 NA A,
-NHSO
2
CH
2
CH
2
NA
1
A
2 , phenyl, imidazolyl, thiazolyl, 4H-[1,2,4]oxadiazol-5-onyl, 4H-pyrrolo[2,3-b]pyrazinyl, pyridinyl, [1,3,4]oxadiazolyl, 4H-[1,2,4]triazolyl, 25 tetrazolyl, pyrazolyl, [1,3,5]triazinyl, or [1,3,4]thiadiazolyl; - 3d Rz and RY are independently H or -C(1.
4 )alkyl, wherein both Rz may have either syn or anti stereochemistry; alternatively both Rz in a syn relationship may be taken together to form -(CH 2 )n 1 -, where n is 2 or 3; 5 R 3 is H, C( 1
.
4 )alkyl, C(1.
3 )alkyl-CF 3 , CH 2
CH
2
NH
2 , CH 2
CH
2 ORa, -COCH 3 ,- CONH 2 , or
-CO
2 Ra; A' is H, -C(1.
4 )alkyl, or CH 2
CH
2 ORa;
A
2 is H, -C(1.
4 )alkyl, CORa, CH 2
CON(CH
3
)
2 , -CH 2
CH
2 ORa, -CH 2
CH
2 SC(1.
4 )alkyl, 0 -CH 2
CH
2 SOC(1.
4 )alkyl, or -CH 2
CH
2
SO
2 C(1.
4 )alkyl; alternatively, AI and A 2 may be taken together with their attached nitrogen to form a heterocyclic ring selected from the following: Ra Raa O N - Ra Ra Ra Ra - RbbN N- - S NJ- O-S Nj , Ra 0 Raa Ra Ra Ra Ra N-- S N - Ra N _// and N Ra 5 wherein Ra is H or C(1.
4 )alkyl; Raa is H or C(1.
4 )alkyl; and Rbb is H, -C(1.
4 )alkyl, -CH 2
CH
2 0CH 2
CH
2 0CH 3 , -CH 2
CO
2 H, -C(O)C(1.
4 )alkyl, or -CH 2 C(O)C(1.
4 )alkyl. 20 According to a third aspect, the present invention provides a use of an effective amount of a compound of Formula I as defined in the first aspect in the manufacture or preparation of a medicament for preventing or treating osteoporosis, Paget's disease, or other diseases in which bone resorption mediates morbidity including rheumatoid arthritis or other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, or tumor 25 metastasis to bone in a mammal.
- 3e The invention also relates to the novel compounds of Formula I: Z NH X J R 2 5 or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein:
R
4
R
4
R
4 HN HN HN W i s N 4 R N N , R~ NNH NN-N 0 R or N ; H wherein each R 4 is independently H, F, Cl, Br, I, OH, OCH 3 , OCH 2
CH
3 , SC(1.
4 )alkyl, 0 SOC(i.
4 )alkyl, SO 2 C(1.
4 )alkyl, -C(1.
3 )alkyl, CO 2 R , CONR R, C-- CRg, or CN; wherein Rd is H, or -C(1.
3 )alkyl; Re is H, or -C(1.
3 )alkyl; R is H, or -C(1.
3 )alkyl; and RI is H, -CH 2 OH, or -CH 2
CH
2 OH; 15
R
2 is cycloalkyl, spiro-substituted cycloalkenyl, heterocyclyl, spirosubstituted piperidinyl, thiophenyl, dihydrosulfonopyranyl, phenyl, furanyl, tetrahydropyridyl, or dihydropyranyl, any of which may be independently substituted with one or two of each of the following: chloro, fluoro, hydroxy, C(1.
3 )alkyl, and C(1.
4 )alkyl; 20 Z is H, F, or CH 3 ; J is CH, or N; -4 RsR10 R10 RZ Xis _ R3 39R 3 R
F
R 9 R
R
93z R 3 R10 OC(1- 4 )alkyl or OC(1- 4 )alkyl Rz is H or -C(1.
4 )alkyl, wherein both Rz may have either syn or anti stereochemistry; alternatively both Rz in a syn relationship may be taken together to form -(CH 2 )n-, where n is 2 or 3; 5
R
3 is H, C(1.
4 )alkyl, CH 2
CH
2
NH
2 , CH 2
CH
2 ORa, -COCH 3 , CONH 2 , or CO 2 Ra;
R
9 is H, C(1.
4 )alkyl, ORa, -NAA 2, NAlSO 2 C(1.
4 )alkyl, NA 1 COC(1.
4 )alkyl,
-NHCH
2
CH
2
OCH
2
CH
3 , -N(CH 2
CH
2
OH)
2 , -N(CH 3
)CH
2
CH
2 0CH 3 ,
-NHCH
2
CH
2
SO
2
CH
3 , -NHCH 2
CON(CH
3
)
2 , or R 3 and R 9 may be taken together to form 0 oxo, -OCH 2
CH
2 0-, or -OCH 2 C(Ra) 2
CH
2 0-; R10 is H, -C(1.
4 )alkyl, -ORa, -CN, -NAA 2 , -SO 2
CH
3 , -COORa, -CO 2
CH
3 , -CH 2 -NA A,
-CONAA
2 , -CH 2 ORa, -OC(1.
4 )alkylORa, -NHCH 2
CH
2
CO
2 Ra, -NHCH 2
CH
2 ORa, -NRa CH 2
CH
2 NAlA 2 , -OC(1.
4 )alkylNAA 2 , -OCH 2
CO
2 Ra, -CH 2
CO
2 Ra, 12 12 12 15 -CH 2
CH
2
SO
2 C(1.
4 )alkyl, -SO 2
CH
2
CH
2 NA1A , -SOCH 2
CH
2 NA A , -SCH 2
CH
2 NA A,
-NHSO
2
CH
2
CH
2
NAA
2 , phenyl, imidazolyl, thiazolyl, 4H-[1,2,4]oxadiazol-5-onyl, 4H-pyrrolo[2,3-b]pyrazinyl, pyridinyl, [1,3,4]oxadiazolyl, 4H-[1,2,4]triazolyl, tetrazolyl, pyrazolyl, [1,3,5]triazinyl, and [1,3,4]thiadiazolyl; 20 A 1 is H, -C(1.
4 )alkyl, or CH 2
CH
2 ORa;
A
2 is H, -C(1.
4 )alkyl, CORa, CH 2
CON(CH
3
)
2 , -CH 2
CH
2 ORa, -CH 2
CH
2 SC(1.
4 )alkyl,
-CH
2
CH
2 SOC(1.
4 )alkyl, or -CH 2
CH
2
SO
2 C(1.
4 )alkyl; -5 alternatively, A' and A 2 may be taken together with their attached nitrogen to form a heterocyclic ring selected from the following: Ra Raa Ra Ra Ra Ra N- - Rbb-N N-- N- O=S Nj , Ra , O ) Raa Ra Ra Ra Ra Ra S N - N N,--z/ _/)-J ,and ~ ; Ra wherein Ra is H or C(1.
4 )alkyl; 5 Raa is H or C(1.
4 )alkyl; Rbb is H, -C(1.
4 )alkyl, -CH 2
CH
2
OCH
2
CH
2
OCH
3 , -CH 2
CO
2 H, -C(O)C(1.
4 )alkyl, or -CH 2 C(O)C(1.
4 )alkyl. Herein and throughout this application, whenever a variable, for example R, appears more than 0 once in an embodiment of Formula I, each such substitution is independently defined. Herein and throughout this application, the terms "Me", "Et", "Pr", and "Bu" refer to methyl, ethyl, propyl, and butyl respectively. Unless the context clearly requires otherwise, throughout the description and the claims, the words "comprise", "comprising", and the like are to be construed in an inclusive sense as 5 opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to". DETAILED DESCRIPTION OF THE INVENTION The invention is directed to novel compounds of Formula I: 20 0W Z N H X J R 2 I or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein: HN\H W is R4R HNK HN, N-N R4 or N R4 H wherein each R 4 is independently H, F, Cl, Br, 1, OH, OCH 3 , OCH 2
CH
3 , SC(.
4 )alkyl,
SOC(.
4 )alkyl, SO 2
C(.
4 )alkyl, -C(.
3 )alkyl, CO 2 Rd, CONR*R, C CRg, or CN; wherein Rd is H, or -C(.
3 )alkyl; 5 R* is H, or -Cg.
3 )alkyl; Rr is H, or -C(b.
3 )alkyl; and Rl is H, -CH 2 OH, or -CH 2
CH
2 OH; R2 is cycloalkyl (including cyclohexenyl, and cycloheptenyl), spiro-substituted 10 cycloalkenyl (including spiro[2.5]oct-5-enyl, spiro[3.5]non-6-enyl, spiro[4.5]dec-7 enyl, and spiro[5.5]undec-2-enyl) heterocyclyl (including piperidinyl), spirosubstituted piperidinyl (including 3-aza-spiro[5.5]undecanyl , and 8-aza spiro[4.5]decanyl), thiophenyl, dihydrosulfonopyranyl, phenyl, furanyl, tetrahydropyridyl, or dihydropyranyl, any of which may be independently 15 substituted with one or two of each of the following: chloro, fluoro, hydroxy, C(l. 3 )alkyl, and C(o.
4 )alkyl (said substituted cycloalkyls include 4,4-dimethyl cyclohexenyl, 4,4-diethyl cyclohexenyl, 4-methyl cyclohexenyl, 4-ethyl cyclohexenyl, 4-n-propyl cyclohexenyl, 4-iso-propyl cyclohexenyl, and 4-tert-butyl cyclohexenyl; said substituted piperidinyls include 4-methyl piperidinyl, 4-ethyl 20 piperidinyl, 4-(1l'hydroxyeth-2'yl)piperidinyl, and 4,4 dimethyl piperidinyl); Z is H, F, or CH 3 ; J is CH, or N; 6 X isR1 R 3
R
9 R R9 R 3 Rz R10 OC(l 4 )alkyl or OC(lA)alkyl RZ is H or -C(- 4 )alkyl, wherein both R 2 may have either syn or anti stereochemistry; alternatively both R' in a syn relationship may be taken together to form -(CH 2 )n-, where n is 2 or 3; 5 R' is H, C(- 4 )alkyl, CH 2
CH
2
NH
2 , CH 2
CH
2 ORa, -COCH 3 , CONH 2 , or CO2Ra Re is H, CI 4 )alkyl, ORa, -NA'A2, NA'S0 2
C(I
4 )akyl, NA'COC( 1
.
4 )alkyl, NHCH 2
CH
2 0CH 2
CH
3 , -N(CH 2
CH
2
OH)
2 , -N(CH 3
)CH
2
CH
2 0CH 3 , 10 NHCH 2
CH
2
SO
2
CH
3 , -NHCH 2
CON(CH
3
)
2 , or R 3 and R 9 may be taken together to form oxo, -OCH 2
CH
2 0-, or -OCH2C(Ra) 2
CH
2 0-;
R
0 is H, -C( 1 A)alkyl, -OR, -CN, -NA'A 2 , -SO 2
CH
3 , -COOPa, -CO 2
CH
3 , -CH 2 NAA 2 , -CONA'A 2 , -CH 2 OR", -OC(lA)alkylOR", -NHCH 2
CH
2
CO
2 Ra, 15 NHCH 2
CH
2 OR", -NRaCH 2
CH
2
NAA
2 , -OC(- 4 )alkylNA'A 2 , -OCH 2
CO
2 Ra,
CH
2
CO
2 Ra, -CH 2
CH
2
SO
2
C(-
4 )alkyl, -SO 2
CH
2
CH
2
NA'A
2 , -SOCH 2
CH
2 NA'A _
SCH
2
CH
2
NA
1
A
2 , -NHSO 2
CH
2
CH
2
NAA
2 , phenyl, imidazolyl, thiazolyl, 4H [1,2,4]oxadiazol-5-onyl, 4H-pyrrolo[2,3-b]pyrazinyl, pyridinyl, [1,3,4]oxadiazolyl, 4H-[1,2,4]triazolyl, tetrazolyl, pyrazolyl, [1,3,5]triazinyl, and [1,3,4]thiadiazolyl; 20 A' is H, -C(p-)alkyl, or CH 2
CH
2 ORa; A2 is H, -C(I,}a1kyl, CORa, CH 2
CON(CH
3
)
2 , -CH 2
CH
2 OR" (including -CH 2
CH
2 0CH 3 ), CH 2
CH
2 SC(wpalkyl (including -CH 2
CH
2
SCH
3 ), -CH 2
CH
2 SCy 4 )alkyl (including CH 2
CH
2
SOCH
3 ), or -CH 2
CH
2
SO
2 C(I-4)alkyl (including -CH 2
CH
2
SO
2
CH
3 ); 7 alternatively, A' and A 2 may be taken together with their attached nitrogen to form a heterocyclic ring selected from the following: Ra RaD Ra Ra Ra Ra Nj- Rbb-N N- -- ,SN O=S Ra R Ra Ra Ra Ra N-D ,and t&Ni Ra wherein Ra is H or C(I-l)alkyl; 5 Raa is H or C(g 4 )alkyl; Rbb is H, -C( 14 )alkyl, -CH 2
CH
2 0CH 2
CH
2 0CH 3 , -CH 2
CO
2 H, C(O)C(1 4 )alkyl, or -CH 2
C(O)C(-
4 )alkyl. In a preferred embodiment of the invention: H 2H W is HN\ NH 2 HN\ N ~~ NCN 0 CI C1 N IYK Br HN\ C, HN\ O N N H N HN HN or X73 N 10 8
R
2 is OH NNN N N or Z is H; J is CH or N; R110 10o Ri io Ri X is R R 3 R9 9R 3 R R 9,or Fq'R 5 wherein R" is H, -CO 2 H, -CN, -OH, -CH 2
NH
2 , -NA'A 2 , -OCH 2
CH
2
NA'A
2 ,or
-NR"CH
2
CH
2
NAA
2 ; A' is H, or -CH 3 ; A2 is H, -CH 2
CH
2 0CH 3 , -COCH 3 , or -CH3; alternatively, A' and A 2 may be taken together with their attached nitrogen 10 to form a heterocyclic ring selected from the following: Ra Raa a a Ra Ra 0 N R- O N-~R RbbN N-- -, N - O=S N Raa ' Ra , a Ra Ra0' N- -R a R Ra Ra %jN- S N1- R ,- / n Ra is H, or -C(I.
4 )alkyl; Raa is H, or -C( 1 .4)alkyl; Rb is H, -C(.
4 )alkyl, -CH 2
CO
2 H or -COCH 3 ; 15 9
R
2 is H, -CH 3 , or may be taken together as -CH 2
CH
2 -; R3 is H, -COCH 3 , -CH 3 , -CO 2
CH
3 , -CONH 2 , or -CQ 2 H;
R
9 is H, -OH, -N(CH 3
)
2 , -N(CH 2
CH
3
)
2 , morpholinyl, N-methyl-piperazinyl, N ethyl- piperazinyl, -NHCH 2
CH
2
OCH
2
CH
3 , -N(CH 2
CH
2
OH)
2 , 5 N(CH 3
)CH
2
CH
2 0CH 3 , -NHCH 2
CH
2
SO
2
CH
3 , -NHCH 2
CON(CH
3
)
2 , or Rmay be taken together with R3 to form oxo, or -OCH 2
CH
2 0-; as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof In another embodiment of the invention: H H Wis HN\ NH 2 HN\ N N1J W is NH2-\, - C1 CI VN H Br HNC HN \ N O N N H HNN 10 or XN R is NN N ror Z is H; J is CH, or N; X is 3or 10 wherein R1 0 is H, -CO 2 H, -CN, -OH, -CH 2
NH
2 , -NA'A 2 , -OCH 2
CH
2
NA'A
2 , or NRaCH 2
CH
2 NA A; A' is H, or -CH 3 ;
A
2 is H, -CH 2
CH
2 0CH 3 , -COCH 3 , or -CH 3 ; 5 alternatively, A' and A 2 may be taken together with their attached nitrogen to form a heterocyclic ring selected from the following: O N]- Rh-N N-- O\S N_ N'N \-/ o \--/ , L , and NA Rbb is H, -C 1
-.
4 )alkyl, -CH 2
CO
2 H or -COCH 3 ; RZ is H, -CH 3 , or may be taken together as -CH 2 CH-; 10 R 3 is H, -COCH 3 , -CH 3 , -CO 2
CH
3 , -CONH 2 , or -CO 2 H;
R
9 is H, -OH, -N(CH 3
)
2 , -N(CH 2
CH
3
)
2 , morpholinyl, N-methyl-piperazinyl, N ethyl- piperazinyl, -NHCH 2
CH
2 0CH 2
CH
3 , -N(CH 2 CH2OH) 2 , N(CH 3
)CH
2
CH
2 0CH 3 , -NHCH 2
CH
2
SO
2
CH
3 , -NHCH 2
CON(CH
3
)
2 , or R9 may be taken together with R3 to form oxo, or -OCH 2
CH
2 0-; 15 as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof In another embodiment of the invention: W is HN N r N
R
2 is N or 20 Z is H; J is CH, or N; 11 X is 3 R 9 , or 10z wherein R is H, -CO 2 H, -CN, -OH, -CH 2
NH
2 , -NAA 2 , -OCH 2
CH
2
NA'A
2 , or NR"CH 2
CH
2
NA'A
2 1; A' is H, or -CH3; 5 A2 is H, -CH 2
CH
2 0CH 3 , -COCH 3 , or -CH 3 ; alternatively, A' and A 2 may be taken together with their attached nitrogen to form a heterocyclic ring selected fi-om the following: 0 Nj Rb-N N O S N_ -- __\ / , o0 _/ , L and N . R is H, -C(l.A)alkyl, -CH 2
CO
2 H or -COCH 3 ; 10 Rz is H, -CH 3 , or may be taken together as -CH 2
CH
2 -;
R
3 is H, -COCH 3 , -CH 3 , -CO 2
CH
3 , -CONH 2 , or -CO 2 H; R9 is H, -OH, -N(CH 3
)
2 , -N(CH 2
CH
3 )2, morpholinyl, N-methyl-piperazinyl, N ethyl- piperazinyl, -NHCH 2
CH
2 0CH 2
CH
3 , -N(CH 2
CH
2
OH)
2 , N(CH 3
)CH
2
CH
2
OGH
3 , -NHCH 2
CH
2
SO
2
CH
3 , -NHCH 2
CON(CH
3
)
2 , or R may be 15 taken together with R3 to form oxo, or -OCH 2
CH
2 0-; as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof In another embodiment of the invention: W is HN HN 20
R
2 is , or Z is H; J is CH, or N; 12 10Rio Ri is R l X is , , or wherein Ri' is -CN, or -OH;
R
3 is -COCH 3 , or -CO 2 H; as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts 5 thereof Yet another embodiment is the compounds of Examples I to 45, and solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, and any combination thereof. 10 Still another embodiment is compounds selected from the group consisting of: N H HN N N HO 0 HO 0 N H N N N HO 0 H Nz N 0
N
4 NH HN H 13 N H N N N N A H and solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof 5 Yet another embodiment is a compound selected from the group consisting of: N HO O CN FH HN N N HO O HO2C CN H N N N -g- N HO O 14 NC N 0 N H CN N H N N N N O H N HN NN O N HO0 CN H HN Q 'N N HO ~ H O N H N Et N N IfA 5 15 N CN 0 H H N H./ ONH \ N CN N N N CN HO)~~~~~ o NandI N N 0 02 and solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof. 5 The invention also relates to methods of inhibiting protein tyrosine kinase activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I. A preferred tyrosine kinase is c-fins. The invention is considered to include the enantiomeric, diastereomeric and 10 tautomeric forms of all compounds of Formula I as well as their racemic mixtures. In addition, some of the compounds represented by Formulae I may be prodrugs, i.e., derivatives of an acting drug that possess superior delivery capabilities and therapeutic value as compared to the acting drug. Prodrugs are transformed into active drugs by in vivo enzymatic or chemical processes. 15 1. Definitons The term alkyll" refers to both linear and branched chain radicals of up to 12 carbon atoms, preferably up to 6 carbon atoms, unless otherwise indicated, and includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, 16 pentyl, isopentyl, hexyl, isohexyl, heptyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl and dodecyl. The term "hydroxyalkyl" refers to both linear and branched chain radicals of up to 6 carbon atoms, in which one hydrogen atom has been replaced with an OH group. 5 The term "hydroxyalkylamino" refers to an hydroxyalkyl group in which one hydrogen atom from the carbon chain has been replaced with an amino group, wherein the nitrogen is the point of attachment to the rest of the molecule. The term "cycloalkyl" refers to a saturated or partially unsaturated ring composed of from 3 to 8 carbon atoms. Up to four alkyl substituents may optionally be present on 10 the ring. Examples include cyclopropyl, 1,1-dimethyl cyclobutyl, 1,2,3 trimethylcyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, and 4,4-dimethyl cyclohexenyl, The term "aminoalkyl" refers to at least one primary or secondary amino group bonded to any carbon atom along an alkyl chain, wherein an alkyl group is the point of 15 attachment to the rest of the molecule. The term "alkylamino" refers to an amino with one alkyl substituent, wherein the amino group is the point of attachment to the rest of the molecule. The term "dialkylamino" refers to an amino with two alkyl substituents, wherein the amino group is the point of attachment to the rest of the molecule. 20 The term "heteroaromatic" or "heteroaryl" refers to 5- to 7-membered mono- or 8 to 10-membered bicyclic aromatic ring systems, any ring of which may consist of from one to four heteroatoms selected from N, 0 or S where the nitrogen and sulfur atoms can exist in any allowed oxidation state. Examples include benzimidazolyl, benzothiazolyl, benzothienyl, benzoxazolyl, furyl, imidazolyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, 25 pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinolinyl, thiazolyl and thienyl. The term "heteroatom" refers to a nitrogen atom, an oxygen atom or a sulfur atom wherein the nitrogen and sulfur atoms can exist in any allowed oxidation states. The term "alkoxy" refers to straight or branched chain radicals of up to 12 carbon atoms, unless otherwise indicated, bonded to an oxygen atom. Examples include methoxy, 30 ethoxy, propoxy, isopropoxy and butoxy. 17 The term "aryl" refers to monocyclic or bicyclic aromatic ring systems containing from 6 to 12 carbons in the ring. Alkyl substituents may optionally be present on the ring. Examples include benzene, biphenyl and napththalene. The term "aralkyl" refers to a C 1
-
6 alkyl group containing an aryl substituent. 5 Examples include benzyl, phenylethyl or 2-naphthylmethyl. The term "sulfonyl" refers to the group -S(O) 2 Ra, where Ra is hydrogen, alkyl, cycloalkyl, haloalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl. A "sulfonylating agent" adds the -S(O) 2 Ra group to a molecule. The term "spiro-substituted cycloalkenyl" refers to a pair of cycloalkyl rings that 10 share a single carbon atom and wherein at least one of the rings is partially unsaturated, for example: The term "spiro-substituted heterocyclyl" refers to a heterocyclyl and cycloalkyl ring that share a single carbon atom, for example: 15 11. Therapeutic Uses The compounds of Formula I represent novel potent inhibitors of protein tyrosine kinases, such as c-fins, and may be useful in the prevention and treatment of disorders resulting from actions of these kinases. The invention also provides methods of inhibiting a protein tyrosine kinase 20 comprising contacting the protein tyrosine kinase with an effective inhibitory amount of at least one of the compounds of Formula I. A preferred tyrosine kinase is c-fms. The compounds of the present invention are also inhibitors of FLT3 tyrosine kinase activity. In one embodiment of inhibiting a protein tyrosine kinase, at least one of the compounds of Formula I is combined with a known tyrosine kinase inhibitor. 25 In various embodiments of the invention, the protein tyrosine kinases inhibited by the compounds of Formula I are located in cells, in a mammal or in vitro. In the case of mammals, which includes humans, a therapeutically effective amount of a pharmaceutically acceptable form of at least one of the compounds of Formula I is administered. 18 The invention further provides methods of treating cancer in mammals, including humans, by administration of a therapeutically effective amount of a pharmaceutically acceptable composition of least one compound of Formula I. Exemplary cancers include, but are not limited to, acute myeloid leukemia, acute lymphocytic leukemia, ovarian 5 cancer, uterine cancer, prostate cancer, lung cancer, breast cancer, colon cancer, stomach cancer,and hairy cell leukemia. The invention also provides methods of treating certain precancerous lesions including myelofibrosis. In one embodiment of the invention, an effective amount of at least one compound of Formula I is administered in combination with an effective amount of a chemotherapeutic agent. 10 The invention further provides methods of treating and of preventing metastasis arising from cancers that include, but are not limited to, ovarian cancer, uterine cancer, prostate cancer, lung cancer, breast cancer, colon cancer, stomach cancer, and hairy cell leukemia. The invention further provides methods for the treatment osteoporosis, Paget's 15 disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone as occurs frequently in cancers including, but not limited to, breast cancer, prostate cancer, and colon cancer. The invention also provides methods of treating pain, in particular skeletal pain 20 caused by tumor metastasis or osteoarthritis, as well as visceral, inflammatory, and neurogenic pain. The invention also provides methods of treating cardiovascular, inflammatory, and autoimmune diseases in mammals, including humans, by administration of a therapeutically effective amount of a pharmaceutically acceptable form of at least one of 25 the compounds of Formula . Examples of diseases with an inflammatory component include glomerulonephritis, inflammatory bowel disease, prosthesis failure, sarcoidosis, congestive obstructive pulmonary disease, idiopathic pulmonary fibrosis, asthma, pancreatitis, HIV infection, psoriasis, diabetes, tumor related angiogenesis, age-related macular degeneration, diabetic retinopathy, restenosis, schizophrenia or Alzheimer's 30 dementia. These may be effectively treated with compounds of this invention. Other 19 diseases that may be effectively treated include, but are not limited to atherosclerosis and cardiac hypertrophy. Autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and other forms of inflammatory arthritis, psoriasis, Sjogren's syndrome, multiple sclerosis, or 5 uveitis, can also be treated with compounds of this invention. The term "therapeutically effective amount" as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation, prevention, treatment, or the 10 delay of the onset or progression of the symptoms of the disease or disorder being treated. When employed as protein tyrosine kinase inhibitors, the compounds of the invention may be administered in an effective amount within the dosage range of about 0.5 mg to about 10 g, preferably between about 0.5 mg to about 5 g, in single or divided daily doses. The dosage administered will be affected by factors such as the route of 15 administration, the health, weight and age of the recipient, the frequency of the treatment and the presence of concurrent and unrelated treatments. It is also apparent to one skilled in the art that the therapeutically effective dose for compounds of the present invention or a pharmaceutical composition thereof will vary according to the desired effect. Therefore, optimal dosages to be administered may be 20 readily determined by one skilled in the art and will vary with the particular compound used, the mode of administration, the strength of the preparation, and the advancement of the disease condition. In addition, factors associated with the particular subject being treated, including subject age, weight, diet and time of administration, will result in the need to adjust the dose to an appropriate therapeutic level. The above dosages are thus 25 exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention. The compounds of Formula I may be formulated into pharmaceutical compositions comprising any known pharmaceutically acceptable carriers. Exemplary carriers include, but are not limited to, any suitable solvents, dispersion media, coatings, antibacterial and 30 antifungal agents and isotonic agents. Exemplary excipients that may also be components of the formulation include fillers, binders, disintegrating agents and lubricants. 20 The pharmaceutically-acceptable salts of the compounds of Formula I include the conventional non-toxic salts or the quaternary ammonium salts which are formed from inorganic or organic acids or bases. Examples of such acid addition salts include acetate, adipate, benzoate, benzenesulfonate, citrate, camphorate, dodecylsulfate, hydrochloride, 5 hydrobromide, lactate, maleate, methanesulfonate, nitrate, oxalate, pivalate, propionate, succinate, sulfate and tartrate. Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamino salts and salts with amino acids such as arginine. Also, the basic nitrogen-containing groups may be quaternized with, for 10 example, alkyl halides. The pharmaceutical compositions of the invention may be administered by any means that accomplish their intended purpose. Examples include administration by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, buccal or ocular routes. Alternatively or concurrently, administration may be by the oral route. 15 Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts, acidic solutions, alkaline solutions, dextrose-water solutions, isotonic carbohydrate solutions and cyclodextrin inclusion complexes. The present invention also encompasses a method of making a pharmaceutical 20 composition comprising mixing a pharmaceutically acceptable carrier with any of the compounds of the present invention. Additionally, the present invention includes pharmaceutical compositions made by mixing a pharmaceutically acceptable carrier with any of the compounds of the present invention. As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified 25 amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts. Polynrphs and Solvates 30 Furthermore, the compounds of the present invention may have one or more polymorph or amorphous crystalline forms and as such are intended to be included in the 21 scope of the invention. In addition, the compounds may form solvates, for example with water (i.e., hydrates) or common organic solvents. As used herein, the term "solvate" means a physical association of the compounds of the present invention with one or more solvent molecules. This physical association involves varying degrees of ionic and 5 covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. The term "solvate" is intended to encompass both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. 10 It is intended that the present invention include within its scope solvates of the compounds of the present invention. Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the means for treating, ameliorating or preventing a syndrome, disorder or disease described herein with the compounds of the present invention or a solvate thereof, which would obviously be included within the scope 15 of the invention albeit not specifically disclosed. 22 Methods of Preparation Scheme 1 Z NO 2 Z NH 2 Z NO2 R Rb J 10Rb J 1) Halogenation 1-3 2) R2M
HR
2 Z NH 2 Reduction Z NO 2 R J R 2 R J R 1-2 1-4 O WpI OW Z NH Z NH Rb J R 2 Rb J R 2 5 1-5 1-6 Scheme 1 illustrates general methodology for the preparation of compounds of Formula I where Rb is X (when X is available in starting material or prepared as shown in later schemes) or compounds of Formula 1-6 where Rb is a leaving group (preferably bromo, chloro, or fluoro) that are useful intermediates used in later schemes. To illustrate 10 the methodology of this scheme, reagents and conditions for the compounds where J is CH are defined. Those skilled in the art will recognize that where J is N, minor modifications of the reaction conditions and preferred reagents may be required. Amines of Formula 1-1 may be commercially available or can be obtained from nitro compounds of Formula 1-0 by reduction using standard synthetic methodology (see 15 Reductions in Organic Chemistry, M. Hudlicky, Wiley, New York, 1984). The preferred conditions are catalytic hydrogenation using a palladium catalyst in a suitable solvent such as methanol or ethanol. In cases where Rb is a halogen and not available as amines of Formula 1-1, nitro reductions may be performed using iron or zinc in a suitable solvent such as acetic acid, or using iron and ammonium chloride in ethanol and water. 23 Compounds of Formula 1-2 where R 2 is cycloalkyl can be obtained by ortho halogenation, preferably bromination, of amino compounds of Formula 1-1 followed by metal-catalyzed coupling reactions with boronic acids or boronate esters (Suzuki reactions, where R 2 M is R 2
B(OH)
2 or a boronic ester, see N. Miyaura and A. Suzuki, Chen. Rev., 5 95:2457 (1995); A. Suzuki in Metal-Catalyzed Coupling Reactions, F. Deiderich, P. Stang, Eds., Wiley-VCH, Weinheim (1988)) or tin reagents (Stille reactions, where R 2 M is
R
2 Sn(alkyl) 3 , see J. K. Stille, Angew. Chem, Int. Ed. EngL., 25: 508-524 (1986)) on the intermediate halo compound. When Rb is Br, an iodo can be introduced such that is reacts preferentially over the bromine in the metal-catalyzed coupling reactions (when J is CH, 10 this compound is commercially available). Preferred conditions for the bromination of 1-1 are N-bromosuccinimide (NBS) in a suitable solvent such as NN-dimethylformamide (DMF), dichloromethane (DCM) or acetonitrile. Metal-catalyzed couplings, preferably Suzuki reactions, can be performed according to standard methodology, preferably in the presence of a palladium catalyst such as tetrakis(triphenylphosphine)palladium(0) 15 (Pd(PPh 3
)
4 ), an aqueous base such aq. Na 2
CO
3 , and a suitable solvent such as toluene, ethanol, 1,4-dioxane, dimethoxyethane (DME), or DMF. Compounds of Formula 1-2 where R 2 is cycloalkylamino (for example, piperidino) can be obtained by nucleophilic aromatic substitution of leaving groups L' (preferably fluoro or chloro) from compounds of Formula 1-3 that are activated by the nitro group with 20 cycloalkylamines (R 2 H; for example, piperidine) in the presence of a suitable base such as
K
2 C0 3 , NN-diisopropylethylamine (DIEA) or NEt 3 to give compounds 1-4, followed by reduction of the nitro group as described above. The amino group in compounds of Formula 1-2 can then be coupled with a heterocyclic acid P-WCOOH (or a corresponding salt thereof P'-WCOOM 2 , where M 2 is 25 Li, Na or K) where P1 is an optional protecting group (for example 2 (trimethylsilyl)ethoxymethyl (SEM) such as when W is imidazole, triazole, pyrrole, or benzimidazole) or where P' is not present such as when W is furan. (For a list of protecting groups for W, see Theodora W. Greene and Peter G. M. Wuts, Protective Groups in Organic Synthesis, John Wiley and Sons, Inc., NY (1991)). The coupling can be 30 carried out according to standard procedures for aide bond formation (for a review, see: M. Bodansky and A. Bodansky, The Practice of Peptide Synthesis, Springer-Verlag, NY 24 (1984)) or by reaction with acid chlorides P 1 -WCOCL or activated esters PI-WCO2R4 (where Rq is a leaving group such as pentafluorophenyl or N-succinimide) to form compounds of Formula 1-5. The preferred reaction conditions for coupling with P' WCOOH or P'-WCOOM 2 are: when W is a furan (optional protecting group P1 not 5 present), oxalyl chloride in dichloromethane (DCM) with DMF as a catalyst to form the acid chloride WCOCI and then coupling in the presence of a trialkylamine such as NN diisopropylethylamine (DIEA); when W is a pyrrole (optional protecting group PI not present), 1-(3-dimethylaninopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) and 1 hydroxybenzotriazole (HOBt); and when W is an imidazole, pyrrole or benzimidazole 10 (optional P1 present) the preferred conditions are bromotripyrrolidinophosphonium hexafluorophosphate (PyBroP) and DIEA in a solvent such as DCM or DMF. When W in compounds of Formula 1-5 contain an optional protecting group P 1 as mentioned previously, it can be removed at this point to give compounds of Formula 1-6. For example, when W is imidazole protected on nitrogen with a SEM group, the SEM 15 group can be removed with either acidic reagents such as trifluoroacetic acid (TFA) or fluoride sources such as tetrabutylammonium fluoride (TBAF) (see Greene and Wuts above). Finally it is understood that in compounds of Formula I (i.e., Formula 1-6 where Rb is X) may be further derivatized. Examples of further derivatization, include, but are not 20 limited to: when compounds of Formula I contain a cyano group, this group may be hydrolyzed to amides or acids under acidic or basic conditions; when compounds of Formula I contain an ester, the ester may be hydrolysed to the acid, and the acid may be converted to amides by the methods described above for amide bond formation. Amides may be converted to amines by a Curtius or Schmidt reaction (for review see, Angew. 25 Chenie Int. Ed., 44(33), 5188-5240, (2005)) or amines may be obtained by reduction of cyano groups (Synthesis, 12, 995-6, (1988) and Chemt. Pharm. Bull., 38(8), 2097-101, (1990)). Acids may be reduced to alcohols, and alcohols may be oxidized to aldehydes and ketones. The preferred conditions for the reduction of a carboxylic acid in the presence of a cyano group include sodium borohydride and ethyl chloroformate in 30 tetrahydrofuran (THF); and alcohol oxidation can be performed using the Dess-Martin periodinane reagent (A dv. Syn. Catalysis, 346, 111-124 (2004)). Aldehydes and ketones 25 may be reacted with primary or secondary amines in the presence of a reducing agent such as sodium triacetoxyborohydride (see J. Org. Chem., 61, 3849-3862, (1996)) to give amines by reductive amination. Olefins may be reduced by catalytic hydrogenation. When compounds of Formula I contain a sulfide, either acyclic or cyclic, the sulfide can be 5 further oxidized to the corresponding sulfoxides or sulfones. Sulfoxides can be obtained by oxidation using an appropriate oxidant such as one equivalent of meta-chloroperbenzoic acid (MCPBA) or by treatment with NaIO 4 (see, for example, J. Med. Chen., 46: 4676-86 (2003)) and sulfones can be obtained using two equivalents of MCPBA or by treatment with 4-methylmorpholine N-oxide and catalytic osmium tetroxide (see, for example, PCT 10 application WO 01/47919). Also, both sulfoxides and sulfones can be prepared by using one equivalent and two equivalents of H202 respectively, in the presence of titanium (IV) isopropoxide (see, for example, J. Chem. Soc., Perkin Trans. 2, 1039-1051 (2002)). 26 Scheme 2 JN NO 2 C0 2
R
2 j N0 NO 2 N0
RCO
2 C2 Z R 3
R
9 R N Rb NO R3 R' 2-2 2.1 1-0 1-4 2-1 If [H]
NH
2 1. Halogenation NH2 R NO2 R I2 2 2 JNHMN O
RO
2 C 2.R2M 3 2C z z z
R
3 R .
R
3 2-4 3 R9 2-5 R2 H
R
2 H R H N W JNN W O J N HO O RaO 2 C / OAN 0 /-- 0 z z z R3 R9 R 3
R
9
R
3
R
9 R 2 H
R
2 H O J NW N NW H 0 2AAN 0 Z z R R 9 2-6 R 3 R 9 5 Scheme 2 illustrates general methodology for the preparation of compounds of -RR 3 R 3 Formula I where X is R 3 R ,or R 27 where R3,R9, and Rz are H, C(o 4 )alkyl or ORa; R") is C0 2
R
3 , CH 2 OH, C(O)NA'A 2 and CH 2
NA
1 A. For the illustration of synthetic strategy in this scheme, reagents and conditions are 5 defined for the substrate where is Rz is H is used in this scheme. Those skilled in the art will recognize that the chemistry is applicable to all X and Rz mentioned with little or minor modifications to reagents and conditions. In addition, although reagents and conditions are defined for the substrate where J is CH, as previously mentioned in Scheme 1, it is also understood that similar synthetic methods can be utilized with minor 10 modifications when J is N. When R2 in Formula I is cycloalkyl (including cycloalkenyl), the sequence begins with compound 2-2 which can be obtained by initial treatment of the ester 2-1 (Ra is C(.. 4 )alkyl) with a suitable base such as lithium hexamethyldidilylamide (LHMDS) or preferably lithium diisopropylamide (LDA), followed by nucleophilic aromatic 15 substitution of the leaving group R (preferably fluoro or chloro) in the 4-halonitrophenyl compound 1--0 (as prepared in Scheme 1) with the resulting anion intermediate. 2-3 can be obtained from nitro compounds 2-2 by reduction using standard synthetic methodology (see Reductions in Organic Chemistry, M. Hudlicky, Wiley, New York, 1984). The preferred conditions are catalytic hydrogenation using a palladium 20 catalyst in a suitable solvent such as methanol or ethanol. Compound 2-4 can be obtained by ortho-halogenation, preferably bromination, of amino compound 2-4 followed by metal-catalyzed coupling reactions with boronic acid or boronate ester (Suzuki reactions, where R 2 M is R 2 B(OH)2 or a boronic ester) or tin reagent (Stille reactions, where R 2 M is R 2 Sn(alkyl) 3 ) on the intermediate halo compound as 25 described in Scheme 1. When R2 in Formula I is cycloalkylamino (for example, piperidino), an alternative method to prepare compound 2-4 begins with starting material 1-4 as described in Scheme 1 where Rb is preferably chloro or fluoro. Compound 2-5 can be obtained from 1-4 and 2 1 by the same method as described for the conversion of compound 1-0 to compound 2-2. 30 Compound 2-4 can then be obtained from compound 2-5 by reduction of the nitro group 28 using standard synthetic methodology as described in Scheme 1 for the conversion of compound 1-0 to compound 1-1. The compounds of Formula I where R1 0 is an ester (R" is Cgapalkyl) can be obtained from 2-4 by initial coupling with carboxylic acids P 1 -WCOOH, followed by 5 removal of the optional protecting group P' according to the procedures as described in Scheme 1 for the conversion of 1-2 to 1-6. These compounds of Formula I where R) is an ester (Ra is C(lA)alkyl) can be further hydrolyzed by an appropriate metal hydroxide reagent such as sodium hydroxide to give compounds of Formula I where R 10 is an acid (Ra is H). 10 The compounds of Formula I where R' 0 is an amide (R 0 is C(O)NRR 6 ) can be obtained from the compounds of Formula I where R4 is an acid (Ra is H) by initial treatment with an alkyl chloroformate, such as ethyl chloroformate, followed by trapping of the intermediate activated acylcarbonate with a suitable primary or secondary amine
(HNAA
2 ), Similarly, compounds of Formula I where R1" is a hydroxymethyl group can 15 be obtained by reaction of the same intermediate activated acylcarbonate with a suitable reducing reagent such as NaBH 4 (see, for example, Tetrahedron, 62(4), 647-65 1; (2006)). Compounds of Formula I where R1 0 is a hydroxymethyl (R1 0 is CH 2 OH) can be further converted to the aldehyde 2-6 by oxidation reactions such as a Swern oxidation (J. Am. Chem. Soc. 102, 1390 (1980)) or perferably a Dess-Martin periodinane oxidation (see, 20 for example, Tetrahedron Lett., 29, 995 (1988); 1. Org. Chem., 55, 1636 (1990)). Aldehyde 2-6 can be reacted with appropriate primary and secondary amines
(HNA'A
2 ) in the presence of suitable reducing reagents such as NaBH 4 or NaBH 3 CN, or preferably NaBH(OAc)3 according to standard procedures for reductive amination as described in Scheme 1, to form compounds of Formula I where R1 0 is an aminomethyl 25 group (R 1 4 is CH 2
NA'A
2 ). It is understood that functional groups of compounds in this scheme can be further derivatized as outlined in Scheme 1. 30 29 Scheme 3 NO2 i NO2 NH 2 Ra02C NC NC z z z Z ZZ R3 R 2-2 R3 R 9 R3 R 3-2 Halogenation
R
2
L
2 2
NH
2
NH
2
NH
2
JR'
0 R FM R? 0 NC z z z 3-3
R
3
R
9 3-4
R
3
R
9 R2 H R 2 R 2 NW NH2 NH2 R' 0 NC Rao 7 7 z R3 R 9
R
3
R
9 3-6 R3 R 9 2-4 R2 H J NN W NN NC 1~ 0 7 R3 R 5 Scheme 3 illustrates general methodology for the preparation of compounds of - 9 R3 JR3 Formula I where X is R R 3 or R9 where R 3
,R
9 , and Rz are H, C( 4 )alkyl or OR'; R1 0 is -CN or heteroaryl. 30 For the illustration of synthetic strategy in this scheme, reagents and conditions are defined for the substrate where R' is H is used in this scheme. Those skilled in the art will recognize that the chemistry is applicable to all X and Rz mentioned with little or minor modifications to reagents and conditions. In addition, although reagents and conditions are 5 defined for the substrate where J is CH, as previously mentioned in Scheme 1, it is also understood that similar synthetic methods can be utilized with minor modifications when J is N. The ester 2-2 (Ra is C( 1 4 )alkyl) can be hydrolyzed by an appropriate metal hydroxide reagent such as sodium hydroxide to give acid 2-2 (Ra is H). The acid 2-2 can 10 be converted to nitrile 3-1 by standard procedures which, in general, begin with activation of the acid, transformation into an amide or hydroxamate followed by dehydration (see, for example, J. Med. Chem., 33(10), 2828-41; (1990)), or preferably in one step by treatment with sulfonamide and thionyl chloride in a suitable solvent such as sulfolane (see, Tetrahedron Lett., 23(14), 1505-08; (1982)). Compound 3-2 can obtained from 3-1 by 15 standard reduction procedures, preferably catalytic hydrogenation as described in Scheme 1. The compound 3-3 (L2 is halogen) can be obtained by ortho-halogenation, preferably bromination, of amine 3-2. Preferred conditions for the bromination of 3-2 are N-bromosuccinimide (NBS) in a suitable solvent such as NN-dimethylformamide (DMF), 20 dichloromethane (DCM) or acetonitrile. At this point the cyano group in 3-3 can be converted to an unsaturated heterocycle in 3-4 by [2+3] cycloaddition with a 1,3 dipole or [2+4] cycloaddition with a dine or heterodiene as illustrated in Scheme 3a. The various heterocycles that can be produced are shown in Table 1 using the conditions in the references provided in the table. 25 When the unsaturated heterocycle present is unreactive toward halogenation, an alternative route to 3-4 involves treatment of nitrile 3-2 as just described to first form the unsaturated heterocycle followed by halogenation to introduce L2 in 3-4. Compound 3-5 can be obtained by metal-catalyzed coupling reactions of 3-4 with boronic acids or boronate esters (Suzuki reactions, where R 2 M is R 2
B(OH)
2 or a boronic ester) or 30 tin reagents (Stille reactions, where R 2 M is R 2 Sn(alkyl) 3 ). The metal-catalyzed couplings, 31 preferably Suzuki reactions, can be performed according to standard methodology as described in Scheme 1. When R 2 in Formula I is cycloalkylamino (for example, piperidino), an alternative method to prepare compound 3-5 begins with starting material 2-4 as prepared in Scheme 5 2. The ester 2-4 (R" is C( 14 )alkyl) can be hydrolyzed by an appropriate metal hydroxide reagent such as sodium hydroxide to give acid 2-4 (Ra is H). The acid 2-4 can be converted to nitrile 3-6 according to the procedures as described for the conversion of 2-2 to 3-1. Compound 3-6 can be converted to compound 3-5 according to the methods as described for the conversion of 3-3 to 3-4. 10 The compounds of Formula I where R1 0 is a nitrile (R1 0 is CN) can be obtained from 3-6 by initial coupling with carboxylic acids P 1 -WCOOH, followed by removal of the optional protecting group P' according to the procedures as described in Scheme I for the conversion of 1-2 to 1-6. Similarly, the compounds of Formula I where R' 0 is an unsaturated heterocycle can 15 be obtained from 3-5 in two steps, namely coupling with a carboxylic acid P'-WCOOH followed by removal of the optional protection group, as described in Scheme 1 for the conversion of 1-2 to 1-6. It is understood that functional groups of compounds in this scheme can be further derivatized as outlined in Scheme 1. 20 Scheme 3a Diene Heterodiene NC or 10 1,3 Dipole R
R
3
R
9 R3 R9 32 Table I Number Name R' Structure Reference: 1 Imidazole N U.S. Pat. Appi HN- 2005101785 (-'N 2 Thiazole S J. Med. Chem., 48(6), N /2167-2175; (2005) 3 4H-[1,2,4]Oxadiazol-5- 0 -N loorganic & one Medicinal Chemistry, N 13(6), 1989-2007 H (2005) 4 4H-Pyrrolo[2,3- Journal of Medicinal b~pyrazine Chemistry, 46(2), 222 N1 N 236; (2003) H H 5 Pyridine / N Journal of Organic I / Chenzisty, 67(13), 4414-4422; (2002) 6 [1,3,4]Oxadiazole /0 Journal ofLabelled N' NN Compounds and Radiopharmaceuticals, 16(5), 753-9; (1979) 7 4H-[1,2,4]Triazole f=N Bioorganic & HN N Medicinal Chemisty Letters, 13(24), 4361 4364; (2003) 8 Tetrazole u Er. Pat. Apple , -N H 648759 N __ _ ___N__ _ _ 9 Pyrazole N H Journal of Organic N Chenistiy, 54(3), 635 40; (1989) 10 [1,3,5)Triazine N Khimiko | ) Farnatsevticheskii NWN Zhurnal, 22(12), 1469 75; (1988) 11 [1,3,4]Thiadiazole Ger. Offen., N/.. 102004009933 5 33 Scheme 4 R2 H R H
R
2 H 9 HN N W RjN W R O N NW
H
2 N I r Rb0 R Z Z Z R43 1-6
R
9 3
R'SO
2 M 1. N3' 0 2. [11] [0 rH N 2 A A N N W 1. S O C I 2 J N N WNRVS R9 N W AWHR N W H or LA. R 8 ' J1 | N z? z R3R 3 3 R R 3 z R'OH, H+ R'SO 2
NH
2 [0] Lewis Acid R y O/R 2 H2 R 2H
R
7 o N W RB NHN NW R-'' N N W R R3 R R3 IP 0 0- 0 R z Rq q6z 9z IR zR 9 R3 5 Scheme 4 describes the synthesis of compounds of Formula I where X is Rio Rio Rio Rio R 9 R JR 10
R
3 , ,orR R3 . For the purpose of illustrating the methodology, reagents and conditions are defined in this scheme for the substrates where 34 Rio X is R 3 and where Rz, R3 and R? are H; and J is CH. Those skilled in the art will recognize that the chemistry is applicable to all X, Rz, R3, R9 and J referenced above can be utilized with minor modifications to the reagents and conditions. The starting material, compound 1-6 where Rb is halogen, preferably Br, is 5 obtained as described in Scheme 1. The halo compound 1-6 can be converted to alcohol 4 1 by initial deprotonation with a suitable base, such as isopropylmagnesium chloride (i PrMgCl), followed by lithium-halogen exchange with an appropriate lithium reagent such as n-butyllithium or preferably tert-butyllithium, and then trapping of the organo-lithium intermediate with an appropriate ketone. Compounds 4-1 is both a compound of Formula I, 10 and can serve as a useful intermediate for the synthesis of other compounds with different groups for Rl'. The tertiary hydroxyl group in compound 4-1 can also be converted to an amino group in compound I (R is NA'A 2 ) by activating 4-1 with a reagent such as thionyl chloride (SOCl 2 ) and trapping of the resulting intermediate(s) with a primary or secondary 15 amine (A 2 A'NH). Compounds of Formula I where Rio is alkoxy (OR 7 ) can be obtained from the hydroxyl compound 4-1 by treatment with acidic reagents such as sulfuric acid or preferably trifluoroacetic acid (TFA) and then trapping of the resulting tertiary cation with an alcohol R 7 OH (where R 7 is CH 2
CH
2
NA'A
2 or CH 2
CH
2 OR" where A',A 2 or R" are not 20 H). The hydroxyl compound 4-1 can also be reacted with a sulfonamide RSSO 2 NRaH in the presence of a Lewis acid (L. A.) such as boron trifluoride diethyl etherate (BF 3 OEt 2 ) in a suitable solvent, such as THF to afford compound I (Rio is NHS0 2 R where R 8 is
CH
2
CH
2
NA'A
2 or Ra where A', A 2 or R' are not H). 25 Compounds of Formula I where Ri is a sulfide (R'" is SR 8 ) can be obtained from compound 4-1 by treatment with acidic reagents such as TFA or Lewis acids such as BF3OEt 2 and then trapping of the resulting tertiary cation with a thiol R 8 SH (where R8 is
CH
2
CH
2
NA'A
2 or R). 35 Compounds of Formula I where R' 0 is a sulfide (R1 0 is SR 8 ) can be further oxidized to the corresponding sulfoxide (Formula I where R1 0 is SOR 8 ) or sulfone ( Formula I where R 0 is S0 2
R
8 ) according to the sulfide oxidation procedures as described in Scheme 1. 5 Compounds of Formula I where Rl' is a sulfone can also be obtained directly from compound 4-1 by reaction with a metal sulfinate salt R8SO 2 M (where M is Na, or K) (see, for example, B. Koutek, et al, Synth. Commun.., 6 (4), 305-8 (1976)). It is understood that functional groups in this scheme can be further derivatized as outlined in Scheme 1. For example, the amino group in compound 4-2 can be reacted with 10 various electrophiles. The amino group can be reacted with carboxylic acids according to standard procedures for amide bond formation or by reaction with acid chlorides or activated esters to form amide compounds as described in Scheme 1. It can be also reacted with an appropriate carbonylation agent, such as phosgene, carbonyldiimidazole or preferably triphosgene, in the presence of a base, such as pyridine or DIEA. The 15 intermediate thus formed can be trapped with a primary or secondary amine, to afford the corresponding urea compound. Similarly, the amino group in compound 4-2 can be reacted with an appropriate oxalylation agent, such as oxalyl chloride, in the presence of a base, such as pyridine or DIEA and the intermediate thus formed can be trapped with a primary or secondary amine to afford oxalamide compounds. Furthermore, the amino 20 group can be reacted with appropriate aldehydes or ketones in the presence of suitable reducing reagents such as NaBH 4 or NaBH 3 CN, or preferably NaBH(OAc)3 according to standard procedures for reductive amination as described in Scheme 1, to form compounds of Formula I where R' 0 is NA A 25 36 Scheme 5
R
2 H R 2 H R 2 H HO~I I
Z
3
F?
3 0 Z R3 4 R 5-1 OH 5-2
R
2 H R 2 H N 0 N 0 Z 0 Z 0 5-4 R2 H y NW .- 0 ANN Z A2 5-5 5 Scheme 5 describes the synthesis of compounds of Formula I where X is RI R0 R10 R10 R R 3 R9, oR 9 where R 1 0 is H or OH. For the purpose of illustrating the methodology, compounds where X comprises a cyclohexane ring are shown in Scheme 5, however those skilled in the art will recognize that the chemistry is applicable to all X shown above. Although reagents and conditions are 10 defined for the substrate where J is CH, as previously mentioned in Scheme 1, it is understood that similar synthetic methods can be utilized with minor modifications when J is N. Compounds of Formula 5-1 can be prepared from compounds of Formula 4-1 (prepared as described in Scheme 4). When R 2 contains an alkene, compounds of formula 15 4-1 can be deoxygenated using stannyl radicals (see, J. Chlem. Soc., Chem. Comm un., 22, 1588-9, (1985) and Prep. Carbohydrate Chent., 151, (1997)) or lithium perchlorate and 37 triethylsilane (see, Tetrahedron Lett., 35, 61-64, (1994). When R2 does not contain an alkene, compounds of formula 4-1 can be deoxygenated in a two-step sequence, first by dehydration using an acid such as TFA to give the alkene, followed by reduction to the alkane using standard methodology such as catalytic hydrogenation (see references 5 Scheme 1). Compounds of Formula 5-1 are also compounds of Formula . Compounds of Formula 5-2 are prepared from compounds of Formula 5-1 where R? is CO 2 Ra (R is C(.
4 )alkyl), and R9 is H by ester hydrolysis using preferably aqueous metal hydroxide solutions such as potassium hydroxide. The acids of Formula 5-2 may be converted into amides of Formula 5-3 by the methods described in Scheme 1. Compounds 10 of formula 5-2 and 5-3 are also compounds of Formula 1. For compounds of Formula 5-1 where R 3 and R9 together form a ketal, deprotection provides ketones of Formula 5-4 (see references in Wuts and Green, cited in Scheme 1). The ketones may then be reduced to alcohols of Formula I or reacted with amines in the presence of a reducing agent such as sodium triacetoxyborohydride (see J. Org. Chen., 61, 15 3849-3 862, (1996)) to give amines of Formula 5-5 which are also compounds of Formula 1. Such amines of Formula I may then be further derivatized according to the methods described in Scheme 1. Finally, the chemistry illustrated above for compounds of Formula 5-1, (ester hydrolysis followed by amide formation, and ketal deprotection to ketones and then 20 conversion to alcohols and amines) also applies to compounds of Formula 4-1 to provide compounds of Formula I where R1 0 is OH. For ketal deprotection in the presence of acid sensitive functionality, LiBF 4 in wet CH 3 CN may be used (see Lipshutz, B. and Harvey, D., Synth. Coinmun., 12, 267 (1982)). 38 Scheme 6 1) 3 R 1) R 3 R9 SNH2 / OTf J NH 2 a M NH2 M 6-2 6-8 R" Z 2) Reduction R 3 2 2) Reduclion Z 6-1 1 -1 1-0 R2 H RN WNO 0 R b R3c Z 2 R 9 5-1 1-3 R -- B(OH)2 6-3 R2 R2 2) HR 2
NH
2 Reduction J NO 2 R3 Z R 3 09 Z 1-2 6-4 5 Scheme 6 illustrates an alternate route to compounds of Formula 5-1 where X is R10 Ri1R0 Ri R9o RI R
R
9 R9 , or and R' 0 is H that are used in Scheme 5 and are also compounds of Formula 1. The methodology is illustrated for cyclohexane but those skilled in the art will recognize that the chemistry applies to all X shown above. Although reagents and conditions are defined for the substrate where J is CH, as previously 10 mentioned in Scheme 1, it is understood that similar synthetic methods can be utilized with minor modifications when J is N. Suzuki coupling of boronic acids (M is B(OH) 2 )(or esters) of 6-1 with vinyl triflates of formula 6-2, followed by alkene reduction gives compounds of Formula 1-1. Alternatively, the sequence may be reversed and boronic acids (or esters) of formula 6-3 15 may be reacted with compounds of formula 1-0, where R is a leaving group (preferably Br, I), followed by reduction to give 1-1. For preferred methodology for Suzuki reactions 39 and reductions see Scheme 1. Vinyl triflates of formula 6-2 are readily available from ketones by enolate formation using an appropriate base such as LDA followed by reaction with N-phenyl bis-trifluoromethane sulfonamide (for reviews Acc. Chen Res., 21, 47, (1998). 5 Compounds of Formula 1-0 are then converted to compounds of Formula 5-1 according to the methodology in Scheme I for the conversion of compounds of Formula 1 0 to compounds of Formula 1-6. The synthesis of compounds of Formula 5-1 where R2 is cycloalkylamino (for example, piperidino) starts with compounds of Formula 1-3 (Rb is bromo or iodo). Suzuki 10 coupling of compounds 1-3 with boronic acids (or esters) of formula 6-3, followed by displacement of I2 (preferable fluoro or chloro) with R 2 H provides compounds of Formula 6-4 (see Scheme 1 for preferred methodology). Alternatively, this sequence may be reversed to also provide compounds of Formula 6-4 (L 2 displacement followed by Suzuki coupling). Reduction of both the nitro and alkene provides compounds of formula 1-2, 15 which are then converted to compounds of Formula 5-1 as described for the conversion of compounds 1-2 to compounds of Formula 1-6 in Scheme 1. Scheme 7 20.
NO
2
L
4 L4 1-2( )1-2 NO 2
R
3
R
9 base j .
R
3 CN 1-2 CN
R
9 1-0 7-1 Scheme 7 describes the synthesis of useful intermediates of formula 1-0 where X is
R
10 Ri 0 Ri 0
R
3 3/ R3 oS ora R R9 . For the purpose of illustrating the 40
R
3 CN -3 1-2 methodology, X is R 9 . Those skilled in the art will recognize that the chemistry is applicable to all X, mentioned with only minor modifications to reagents and conditions. In addition, although reagents and conditions are defined for the substrates where J is CH, as previously mentioned in Scheme 1, it is also understood that similar synthetic methods 5 can be utilized with minor modifications when J is N. Commercially available starting material 7-1 can be reacted in a suitable solvent such as EtOH, THF, DME, or preferably DMF, with at least two equivalents of a suitable base such as potassium tert-butoxide, NaOEt, LDA, LHMDS or preferably NaH, and a L4 L4 1-2( K, ft11-2 reagent containing two leaving groups L 4 such as R3 R9 to obtain compound 1-0. 10 These reagents with leaving groups are either commercially available or can be easily prepared. The suitable leaving groups L4 are mesylates, tosylates, triflates and halogens such as Br, Cl, and 1. 15 Scheme 8 H R N N Halogenation R 0 N /,> 1> \ pa N pa a N
P
1
P
1 8-1 8-2 8-3 R d N 0 N 0 MOH pa N OM pa N !o P8 P 8-5 8-4 41 Scheme 8 illustrates a route to the preparation of 2-imidazolecarboxylates of Formula 8-5 where Ra is H or C(.
4 )alkyl, and Rd is H, alkyl, -CN, or -CONH 2 that are used as intermediates in the synthesis of compounds of Fornula I where W is imidazole. Imidazoles of Formula 8-1 where R' is H or C(_ 4 )alkyl, and R' is H, C(_ 4 )alkyl or 5 CN are either commercially available or, in the case where R' is -CN, are readily available from commercially available aldehydes (8-1 where R' is CHO) by reaction with hydroxylamines followed by dehydration with a suitable reagent such as phosphorus oxychloride or acetic anhydride (Synthesis, 677, 2003). Imidazoles of Formula 8-1 are protected with a suitable group (P') such as a methoxymethylamine (MOM), or preferably 10 a SEM group to give compounds of Formula 8-2 (see Theodora W. Greene and Peter G. M. Wuts, Protective Groups in Organic Synthesis, John Wiley and Sons, Inc., NY (1991)). Imidazoles of Formula 8-2, where R' is -CN, are halogenated with a suitable reagent such as N-bromosuccinimide or N-iodosuccinimide under either electrophilic conditions in a solvent such as DCM or CH 3 CN or under radical conditions in the presence 15 of an initiator such as azobis(isobutyronitrile) (AIBN) in a solvent such as CC1 4 to give compounds of Formula 8-3 where L8 is a leaving group (preferably bromo or iodo). Halogen-magnesium exchange on compounds of Formula 8-3 provides the organomagnesium species, which is then reacted with a suitable electrophile to provide compounds of Formula 8-4. The preferred conditions for halogen-magnesium exchange 20 are using an alkyl-magnesium reagent, preferably isopropylmagnesium chloride in a suitable solvent such as THF at temperatures between -78 *C - to 0 'C. The preferred electrophiles are ethyl chloroformate or ethyl cyanoformate. For examples of halogen magnesium exchange on cyanoimidazoles see J. Org. Chem. 65, 4618 , (2000). For imidazoles of Formula 8-2, where R' is not -CN, these may be converted 25 directly to imidazoles of Formula 8-4 by deprotonation with a suitable base such as an alkyllithium followed by reaction with an electrophile as described above for the organomagnesium species. The preferred conditions are treating the imidazole with n butyllithium in THF at -78 C and quenching the resulting organolithium species with ethyl chloroformate (for examples, see Tetrahedron Lett., 29, 3411-3414, (1988)). 30 The esters of Formula 8-4 may then be hydrolyzed to carboxylic acids (M is H) or carboxylate salts (M is Li, Na, or K,) of Formula 8-5 using one equivalent of an aqueous 42 metal hydroxide (MOH) solution, preferably potassium hydroxide in a suitable solvent such as ethanol or methanol. Synthesis of compounds of Formula 8-5 where R is CONH 2 is accomplished by first treating compounds of Formula 8-4 where R4 is -CN with an appropriate alkoxide such as potassium ethoxide to convert the cyano group to an 5 imidate group (Pinner reaction) followed by hydrolysis of both the ester and imidate groups with two equivalents of an aqueous metal hydroxide solution. Scheme 9 10 Re N M Re N O N MON OM 0 9-2 9-3 N 0 9R N MOHR J>O Re 0 O Re N OM P P 9-4 9-5 Scheme 9 illustrates a route to 2-imidazolecarboxylates of Formula 9-3 or 9-5 where Re is chloro or bromo, and M is H, Li, K, or Na that are used as intermediates in the synthesis of compounds of Formula I where W is imidazole. 15 Compounds of Formula 9-1 are first prepared by protection of commercially available ethyl imidazolecarboxylate according to the methods outlined in Scheme 8, preferably with a SEM group. Compounds of Formula 9-2 are prepared by reaction of compounds of Formula 9-1 with one equivalent of an appropriate halogenating reagent, such as NBS or NCS in a 20 suitable solvent such as CH 3 CN, DCM or DMF at 25 'C. Compounds of Formula 9-4 are prepared by reaction of compounds of Formula 9-1 with two equivalents of an appropriate halogenating reagent, such as NBS or NCS in a suitable solvent such as CH 3 CN or DMF at 43 temperatures between 30 *C to 80 "C. Imidazoles of Formula 9-3 and 9-5 are then obtained from the respective esters by hydrolysis as described in Scheme 8. 5 Scheme 10 0 0 I0 P O - 0 P 1 O P, O N / AO N / MO N |1p-8 ,1| -s ,|pn N N N 10-1 10-2 10-3 Scheme 10 illustrates a Tethod for the preparation of imidazoles of Formula 10-3 where R is -SCH 3 , -SOCH 3 ,or -SO 2
CH
3 , M is H, Li, K, or Na that are used as 10 intermediates in the synthesis of compounds of Formula I where W is imidazole. Imidazole 10-1 (WO 1996011932) is protected according to the methods described in Scheme 8, preferably with a SEM protecting group to give compounds of Formula 10-2. Ester hydrolysis according to the procedure in Scheme 8 gives compounds of Formula 10 3 where Rf is -SCH 3 . Oxidation of 2-methylthioimidazoles of Formula 10-2 with one 15 equivalent of an appropriate oxidant, followed by ester hydrolysis according to the procedure in Scheme 8 gives compounds of Formula 10-3 where R/is -SOCH 3 . Oxidation with two equivalents of an appropriate oxidant, followed by ester hydrolysis according to the procedure in Scheme 8 gives compounds of Formula 10-3 where Rfis -SO 2
CH
3 . The preferred reagent for oxidation is MCPBA in DCM. References for the conversion of 20 sulfides to sulfoxides and sulfones are given in Scheme 1. The following examples are for exemplary purposes only and are in no way meant to limit the invention. 25 Example 1 4-Cyano-1H-imidazole-2-carhoxylic acid [2-(4,4-dimethyl-cyclohex--enzyl)-4-(1 hydroxy-cyclohexyl)-phenyl]-amnide 44 N N HO 0 a) 1-(2-Trimetliylsilanyl-ethoxyimetlyl)-IH-imidazole-4-carbonitrile NC N N SEM A flask charged with imidazole-4-carbonitrile (0.50 g, 5.2 mmol) (Synthesis, 677, 5 2003), 2-(trimethylsilyl)ethoxymethyl chloride (SEMCI) (0.95 mL, 5.3 mmol), K 2 C0 3 (1.40 g, 10.4 mmol), and acetone (5 mL) was stirred for 10 h at RT. The mixture was diluted with EtOAc (20 mL), washed with water (20 mL), brine (20 mL) and the organic layer was dried over MgSO 4 . The crude product was eluted from a 20-g SPE cartridge (silica) with 30 % EtOAc/hexane to give 0.80 g (70 %) of the title compound as a colorless 10 oil. Mass spectrum (CI (CH 4 ), m/z): Calcd. for CiOH17N 3 OSi, 224.1 (M+H), found 224.1. b) 2-Bromno-1-(2-trimethylsilanyl-ethoxymethyl)-JH-imidazole-4-carbonitrile NC N I j-Br N SEM To a solution of 1-(2-trimethylsilanyl-ethoxymethyl)- 1H-imidazole-4-carbonitrile 15 (0.70 g, 3.1 mmol) (as prepared in the previous step) in CCl 4 (10 mL) was added N bromosuccinimide (NBS) (0.61 g, 3.4 mmol) and azobis(isobutyronitrile) (AIBN) (cat), and the mixture was heated at 60 *C for 4 h. The reaction was diluted with EtOAc (30 mL), washed with NaHCO 3 (2 x 30 mL), brine (30 mL), the organic layer was dried over Na 2
SO
4 and then concentrated. The title compound was eluted from a 20-g SPE cartridge 20 (silica) with 30 % EtOAc/hexane to give 0.73 g (77 %) of a yellow solid. Mass spectrum (CI (CH 4 ), n/z): Calcd. for CioH 16 BrN 3 OSi, 302.0/304.0 (M+H), found 302.1/304.1. 45 c) 4-Cyano-1-(2-trimethylsilanyl-etoxymnetlzy)-H-iiidazole-2-car'boxylic acid ethyl ester NC N N O SEM To a solution of 2-bromo-1-(2-trimethylsilanyl-ethoxymethyl)- IH-imidazole-4 5 carbonitrile (0.55 g, 1.8 mmol) (as prepared in the previous step) in tetrahydrofuran (THF) (6 mL) at -40 *C was added dropwise a solution of 2 M i-PrMgCl in THF (1 mL). The reaction was allowed to stir for 10 min at -40 *C and then cooled to -78 'C, and ethyl cyanoformate (0.30 g, 3.0 mmol) was added. The reaction was allowed to attain RT and stirred for I h. The reaction was quenched with satd aq NH 4 Cl, diluted with EtOAc (20 10 mL), washed with brine (2 x 20 mL). The organic layer was dried over Na 2
SO
4 and then concentrated. The title compound was eluted from a 20-g SPE cartridge (silica) with 30 % EtOAc/hexane to give 0.40 g (74 %) of a colorless oil. Mass spectrum (ESI, m/z): Caled. for C 13
H
2 1
N
3 0 3 Si, 296.1 (M+H), found 296.1. 15 d) 4-Cyano-1-(2-timethylsilanyl-etoxymethyl)-JH-imnidazole-2-carboxylate potassium salt NC N O~K* N O SEM To a solution of 4-cyano-l-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2 carboxylic acid ethyl ester (0.40 g, 1.3 mnol) (as prepared in the previous step) in ethanol 20 (3 mL) was added a solution of 6M KOH (0.2 mL, 1.2 mmol) and the reaction was stirred for 10 min and then concentrated to give 0.40 g (100 %) of the title compound as a yellow solid. 'H-NMR (CD 3 0D; 400 MHz): 6 7.98 (s, 1H), 5.92 (s, 2H), 3.62 (m, 2H), 0.94 (m, 2H), 0.00 (s, 9H). Mass spectrum (ESI-neg, m/z): Caled. for C 11
H
16
KN
3 0 3 Si, 266.1 (M K), found 266.0. 25 e) 4-Bromno-2-(4,4-dimethyl-cyclohex-1-enyl)-phenylamine 46
NH
2 Br A flask is charged with 4-bromo-2-iodo-phenylamine (1.10 g, 3.70 mmol), 4,4 dimethylcyclohexen-1-ylboronic acid (0.630 g, 4.07 mmol), Pd(PPh 3
)
4 (0.24 g, 5 mol %), 2 M Na 2
CO
3 (16 mL), EtOH (16 mL) and toluene (32 mL) and heated at 80 'C for 6 h. The 5 reaction was diluted with EtOAc (100 mL) and washed with saturated aqueous NaHCO 3 (2 x 100 mL) and brine (100 mL), and the organic layer dried over Na 2
SO
4 and evaporated. The crude product was purified by flash silica gel chromatography eluting with 10% EtOAc/hexanes to give 0.680 g (66%) of the title compound as a light yellow oil. Mass spectrum (ESI, m/z): Caled. for C 14 HigBrN, 280.1 (M+H), found 280.1. 10 f) 4-Cyano-1-(2-trimnethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid [4 broimo-2-(4,4-dimethyl-cyclohex-1-enyl)-phenylJ-amide SEM 0 N ANH N NC Br To a suspension of 4-bromo-2-(4,4-dimethyl-cyclohex-1-enyl)-phenylamine (0.640 15 g, 2.29 mmol) (prepared in the previous step) and 4-cyano-1-(2-trimethylsilanyl ethoxymethyl)-1H-imidazole-2-carboxylate potassium salt (0.700 g, 2.30 mmol) (prepared in this example, step (d)) in DCM (12 mL) was added DIPEA (0.800 mL, 4.60 mmol) and PyBroP (1.29 g, 2.76 mmol) and the mixture allowed to stir at RT for 10 h. The mixture was diluted with DCM (50 rnL) and washed with NaHCO 3 (2 x 50 mL) and the organic 20 layer dried over Na 2
SO
4 and concentrated. The title compound was eluted from a 20-g SPE with 1:1 D CM/hexanes to give 1.04 g (86%) of the title compound as a white solid. Mass spectrum (ESI, m/z): Calcd. for C 2 5
H
3 3 BrN 4 0 2 Si, 529.1 (M+H), found 529.1. 47 g) 4-Cyano-JH-imidazole-2-carboxylic acid [4-broimo-2-(4,4-dimethyl-cyclohex-1-eny) phenyl]-amide 0 N NC NH NH Br To a solution of 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)- 1 H-imidazole-2 5 carboxylic acid [4-bromo-2-(4,4-dimethyl-cyclohex-1-enyl)-phenyl]-amide (0.95 g, 1.80 mmol) (prepared in the previous step) in 10 mL of DCM was added 0.4 mL of EtOH and 10 mL of TFA and the mixture stirred for 1 h at RT. The mixture was concentrated and triturated with Et 2 0 to give 0.68 g (95%) of a white solid: 'H-NMR (400 MHz, CDCls): 8 11.23 (br s, 1H), 9.52 (br s, 1H), 8.27 (d, J = 8.7 Hz, 1H), 7.72 (s, 1H), 7.41 (dd, J = 2.3, 10 8.7 Hz, IH), 7.33 (d, J = 2.3Hz, 1H), 5.82 (m, 1H), 2.28 (m, 2H), 2.10 (in, 2H), 1.58 (in, 211), 1.08 (s, 6H). Mass spectrum (ESI, m/z): Calcd. for C 19
H
19 BrN 4 O, 399.1 (M+H), found 399.0. h) 4-Cyano-1H-imidazole-2-carboxylic acid [2-(4,4-diimethyl-cyclohex-1-enyl)-4-(1 15 hydroxy-cyclohexyl)-phenyl-amide A solution of 4-cyano-1 H-imidazole-2-carboxylic acid [4-bromo-2-(4,4-dimethyl cyclohex-1-enyl)-phenyl]-amide (159 mg, 0.397 mmol, as prepared in Example 1, step (g)) in THF (15 mL) was placed under Ar, cooled to -78 'C, and treated with i-PrMgCl (199 pL, 0.397 mmol). The mixture was warmed to RT, allowed to stir at that temperature for 20 10 min, cooled to -78 0 C, treated with t-BuLi (701 L, 1.19 mmol), stirred at that temperature for 10 min, and then treated with cyclohexanone (411 pL, 3.97 mmol). The mixture was warmed to RT, stirred 1.5 h, quenched with satd aq NH 4 CI (20 mL), and extracted with EtOAc (2 x 50 mL). The combined organic layers were dried over MgSO 4 and concentrated in vacuo. Silica gel chromatography of the residue with 25-50 % EtOAc 25 hexane on a 20-g Isolute SPE column afforded 75.0 mg (45 %) of the title compound as a white solid. 'H-NMR (CD 3 0D; 400 MHz): 6 12.11-11.91 (br s, IHI), 9.63 (s, 1H), 8.31 (d, 1H, J= 8.4 Hz), 7.71 (s, 1H), 7.43 (dd, 1H, J = 8.4, 2.0 Hz), 7.36 (d, 1H, J= 2.0 Hz), 5.82 48 5.75 (m, 1H), 3.77-3.67 (m, 1H), 2.62-2.53 (m, IH), 2.42-2.24 (in, 4H), 2.17-2.07 (m, 2H), 1.96-1.55 (m, 10H), 1.10 (s, 6H). Mass spectrum (ESI, m/z): Caled. for C 25
H
30 N0 2 , 419.2 (M+H), found 419. 1. 5 Example 2 4-[4-[(5-Cyano-1H-iimidazole-2-carbonyl)-amino]-3-(4,4-dimethyl-cyclohex--enyl) phenyl]-cis-4-hydroxy-cyclohexanecarboxylic acid CN H HN N N N HO I
HO
2 C 10 a) 4-[4-[(4-Cyano-1H-imidazole-2-carbonyl)-aminoJ-3-(4,4-dimethyl-cyclohex-1-enyl) phenyl]-cis-4-hydroxy-cyclohexanecarboxylic acid ethyl ester HNN H HN ~Z N HO O E10 2 C To a suspension of 4-cyano-1H-imidazole-2-carboxylic acid [4-bromo-2-(4,4 dimethyl-cyclohex-1-enyl)-phenyl]-amide (65 mg, 0.16 mmol) (prepared in Example 1, 15 step (g)) in 5 mL THF at -40 'C was added i-PrMgCI (0.20 mL, 0.40 mmol, 2 M in THF) and the solution was then warmed to 0 *C and stirred for 10 min. The solution was then cooled to -78 *C and t-BuLi (0.25 mL, 0.42 mmol, 1.7 M in pentane) was added dropwise over 2 min and then 4-oxo-cyclohexanecarboxylic acid ethyl ester (0.13 mL, 0.80 mmol) was added immediately thereafter. After 5 min at -78 *C the reaction was quenched with 49 satd NH 4 CI (10 mL) and extracted with EtOAc (3 x 10 mL) and dried over Na 2
SO
4 . The title compound was used in the next step without further purification. b) 4-[4-[(4-Cyano-IH-imidazole-2-carbonyl)-amino]-3-(4,4-dimethyl-cyclohex--enyl) 5 phenylJ-cis-4-hydroxy-cyclohexanecarboxylic acid To a solution of 4-[4-[(4-cyano-1H-imidazole-2-carbonyl)-amino]-3-(4,4-diinethyl cyclohex-1-enyl)-phenyl]-cis-4-hydroxy-cyclohexanecarboxylic acid ethyl ester (50 mg, 0.10 mmol)(prepared in the previous step) in 1 mL of EtOH was added 2N KOH (0.16 mL, 0.32 mmol) and the reaction stirred at RT for 2 h. The mixture was diluted with 5 mL of 10 H20, the pH adjusted to 2 with 2M TFA/H 2 0, and the title compound was purified by RP HPLC on a C1 8 column eluting with a linear gradient of 30-50% CH3CN in 0.1%
TFA/H
2 O over 10 min to give 14 mg (19%, steps (a) and (b)) of a white solid. IH-NMR (400 MHz, CD 3 0D): 8 8.13 (d,J= 8.6 Hz, 1H), 7.98 (s, 1H), 7.39 (dd,J= 8.6, 2.2 Hz, 1H), 7.34 (d, J = 2,2 Hz, lH), 5.72 (m, 1H), 2.39 (m, 1H), 2.34-2.27 (m, 2H), 2.09-1.77 15 (m, 10H), 1.58 (t, J = 6.2 Hz, 1H), 1.07 (s, 6H). Mass spectrum (ESI, m/z): Caled. for
C
26
H
30
N
4 0 4 , 461.2 (M-H), found 461.3. 20 Example 3 4-Cyano-1H-iimidazole-2-carboxylic acid [2-(4,4-dimnethyl-cyclohex-1-enyl)-4-(1 hydroxy-cyclopenityl)-phenyll-aimide CN H N N N HO I 0 H 25 The title compound was prepared as described in Example 1, step (h) using 4 cyano- 1 H-inidazole-2-carboxylic acid [4-bromo-2-(4,4-dimethyl-cyclohex- 1 -enyl) phenyl]-amide (as prepared in Example 1 step (g)) and cyclopentanone. Mass spectrum (ESI, m/z): Calcd. for C 24
H
28
N
4 0 2 , 405.2 (M+H), found 405.1. 50 Example 4 4-Cyano-1H-imidazole-2-carboxylic acid [4-(1-cyano-cyclopropyl)-2-(4,4-dimethyl cyclohex.-1-enyl)-phenylJ-amide 5 NC N 0 N H ON a) 1-(4-Amino-phenyl)-cyclopropanecarbonitrile N H 2 CN 10 To a solution of 1-(4-nitro-phenyl)-cyclopropanecarbonitrile (500 mg, 2.65 mmol, Journal of the American Chemical Society, 71, 2031-5; 1949) in 7 mL of EtOH- 2.5 mL of EtOAc was added 350 mg 5% Pd-C. The mixture was stirred under I atm of H2 overnight. 15 The reaction was filtered, concentrated in vacuo and then purified using preparative thin layer chromatography (CHC1 3 ) to afford the title compound as an oil (96 mg, 23%). Mass spectrum (ESI, m/z): Cald. CioHION 2 , 159.0, found 159.2, b) 1-[4-Amino-3-(4,4-dimethyl-cyclohex-1-enyl)-phenyl]-cyclopropanecarbonitrile
NH
2 CN 20 51 To a solution of 1-(4-amino-phenyl)-cyclopropanecarbonitrile (96 mg, 0.60 mmol) in MeCN (3 mL) at 0 'C was added NBS (108 mg, 0.60 mmol) and the reaction was allowed to stir overnight. The reaction was diluted with EtOAc (25 mL) and was then washed with saturated aqueous NaHCO 3 (1 x 25 mL). The organic layer was dried 5 (Na 2
SO
4 ) and concentrated in vacuo to give 114 mg (80 %) of 1-(4-amino-3-bromo phenyl)-cyclopropanecarbonitrile. The crude product was used without further purification. The title compound was prepared from 1-(4-amino-3-bromo-phenyl) cyclopropanecarbonitrile (as prepared in this step) and 4,4-dimethylcyclohexen-1-yl 10 boronic acid using the conditions described in Example 1, step (e). 1 H NMR (CD 3 0D; 400 MHz): 8 6.95 (dd, 1H, J = 8.2, 2.3 Hz), 6.88 (d, 1H, J = 2.3 Hz,), 6.71 (d, 1H, J = 8.2 Hz), 5.62 (m, IH), 2.52-2.23 (m, 2H), 1.98-1.97 (m, 2H), 1.55-1.51 (m, 4H), 1.31-1.28 (m, 2H), 1.01 (s, 6H). 15 c) 4-Cyano-1-(2-trimetlhylsitanyl-ehoxymnetizyl)-1H-imidazole-2-carboxylic acid [4-(1 cyano-cyclopropyl)-2-(4,4-dimethyl-cyclohex-1-enyl)-phenyl]-amide NC N 0
<K
0 Me 3 Si CN 20 The title compound was prepared from 1-[4-amino-3-(4,4-dimethyl-cyclohex-1 enyl)-phenyl]-cyclopropanecarbonitrile (as prepared in the previous step) using the conditions described in Example 1, step (f). 'H NMR (CDCl 3 ; 400 MHz): 8 9.74 (s, 1H), 8.36 (d, 1H, J = 9.3 Hz), 7.15 (m, 1H), 5.93 (s, 2H), 5.76 (m, 1H), 3.67-3.63 (m, 2H), 2.27 2.25 (m, 2H), 2.10-2.09 (m, 2H), 1.72-1.69 (m, 2H), 1.59 (t, IH, J = 6.28 Hz), 1.41-1.38 25 (m, 2H), 1.11 (s, 6H), 0.99-0,94 (m, 2H), 0.00 (s, 9H). 52 d) 4-Cyano-1H-imidazole-2-carboxylic acid [4-(1-cyano-cyclopropyl)-2-(4,4-dimethyl cyclohex-1-enyl)-phenyl]-amnide The title compound was prepared from 4-cyano- I -(2-trimethylsilanyl 5 ethoxymethyl)-1H-imidazole-2-carboxylic acid [4-(1-cyano-cyclopropyl)-2-(4,4-dimethyl cyclohex- 1 -enyl)-phenyl]-amide (as prepared in the previous step) using the conditions described in Example 1, step (g). 'H NMR (CD 3 0D; 400 MHz): 6 8.24 (d, 1H, J = 8.4 Hz), 7.99 (s, IH), 7.24-7.22 (m, 1H), 7.17 (s, 1H), 5.76 (s, 1H), 2.30 (br s, 2H), 2.08 (br s, 2H), 1.69 (br s, 2H), 1.60 (t, 2H, J = 6.01 Hz), 1.47 (br s, 2H), 1.00 (s, 6H). Mass 10 spectrum (ESI, m/z): Calcd. for C 23
H
2 3
N
5 0, 386.1 (M+H), found 386.1. The following examples are produced according to procedures of previous examples with the corresponding reagents as indicated in the table below: Ex- Name Structure Procedure Reagents ample Reference No. 4-Cyano-1H-imidazole-2- H O Cyclopentanone 5 carboxylic acid [2-(4,4- N NH Ex 1, step N dimethyl-cyclohex-1-enyl)- (h), morpholine NC 4-(1-morpholin-4-yl- Ex. 43. cyclopentyl)-phenylJ- N amide O 4-Cyano-1H-pyrrole-2- H 0 Cyclopentanone 6 carboxylic acid [2-(4,4- N NH Ex 1, dimethyl-cyclohex-1-enyl)- / steps Morpholine NC 4-(1-morpholin-4-yl- (e),(f),(h) H ,N 0 cyclopentyl)-phenyl]- N Ex 43. amiide O NC OH (Canadian J. 53 Chem. 59, 2673 (1981)) 4-Cyano-lfH-imidazole-2- H N H 2 7 carboxylic acid [4-[1-(2- NH Ex 1, dimethylamino-ethoxy)- stepsN( ste NC cyclobutyl]-2-(4-methyl- (h), Br (WO piperidin-1-y)-phenyl]- o Ex. 36 2005131022, amide N A1) cyclobutanone; 2 dimethylamino ethanol 4-Cyano-1H-pyrrole-2- H 0 Ex 1 step NH 2 8 carboxylic acid J4-[1-(2- N NH (f),(h), N dimethylamino-ethoxy)- Ex 36. NCN cyclobutyl]-2-(4-methyl- Br (WO piperidin-1-yl)-phenylJ- 0 2005131022, amide AN A1) cyclobutanone; 2 dimethylamino ethanol 4-Cyano-1H-Imidazole-2- H 0 Ex. 1, step Cyclohexanone; 9 carboxylic acid (2-(4,4- N N H (h); 1-(2-hydroxy dimethyl-cyclohex-1-eny)- /N Ex 36 ethyl)imidazole NC 4-[1-(2-nidazol-1-yl ethoxy)-cyclohexyll- 0 phenyl}-amide N 54 4-Cyano-1H-imidazole-2- H 0 Ex. 1, N NH 10 carboxylic acid {4-[1-(4- | steps (e) ethyl-piperazin-1-yl)- NC (h); cyclopentylj-2- Ex 43. -B'O spiro[4.5]dec-7-en-8-yl- - N phenyl}-amide (WO 2005063705); cyclopentanone, 1-ethyl piperazine 4-Cyano-1H-imidazole-2- H 0 Ex. 1, N NHe steps (el 11 carboxylic acid [4-(1- N I dimethylamino- N(h); cyclobutyl)-2- Ex 43 spiro[4.5jdec- 7-en-8-yl- N phenyl]-ainide (WO 2005063705); cyclobutanone, dimethylamine 4-Cyano-JH-imnidazole-2- H 0 Ex. 1, 12 carboxylic acid {4-[]-(2- | I steps (e) dimethylamino-ethoxy)- NC (h); cyclopentylJ-2- Ex 36 spiro[4.5]dec-7-en-8-yl phenyl}-amide (WO 2005063705); cyclopentanone, 2-dimethyl aminoethanol 55 4-Cyano-1H-pyrrole-2- H 0 Cyclobutanone; 13 carboxylic acid {2-(4,4- N NH Ex 1 steps 1-methyl diiethyl-cyclobex-1-enyl)- / (e),(f),(h), piperazine NC 4-[1-(4-metzyl-piperazin- Bx. 43 1-yl)-cyclobutyl]-phenylj- N amide Example 14 4-Cyano-1H-imidazole-2-carboxylic acid [4-(1-cyano-cyclohexyl)-2-(4,4-dimethyl 5 cyclohex-1-enyl)-phenyl}-aimide N H N N N N H a) 1-(4-Nitro-phenyl)-cyclohexanecarbonitrile
NO
2 10 A slurry of NaH (711 mg, 29.6 mmol) in DMSO (10 mL) and THF (3 mL) was treated portionwise slowly with (4-nitro-phenyl)-acetonitrile (2.00 g, 12.3 mmol) and stirred at RT for 5 min until H 2 evolution ceased. A solution of dibromopentane (2.02 mL, 14.8 mmol) in THF (10 mL) was added to the slurry over 10 min. The mixture was stirred at RT for an additional 5 min, placed in an oil bath at RT, slowly warmed to 70 'C, and 15 stirred at 70 *C for 1 h. The cooled mixture was diluted with EtOAc (250 mL) and washed with water (3 x 100 mL) and brine (2 x 100 mL). The combined aqueous layers were 56 extracted with EtOAc (1 x 100 mL). The combined organic layers were dried over MgSO 4 and concentrated in vacuo. Silica gel chromatography of the residue on a 50-g Varian MegaBond Elut SPE column with 10 % EtOAc-hexane afforded the title compound (1.46 g, 51 %) as a tan solid. 1 H-NMR (CDC 3 ; 400 MHz): 6 8.26 (d, 2H, J = 8.4 Hz), 7.69 (d, 5 2H, J = 8.4 Hz), 2.21-2.13 (m, 2H), 1.98-1.74 (m, 8H). b) 1-(4-Amino-phenyl)-cyclohexane carbonitrile NH2 N N. 2 A solution of 1-(4-nitro-phenyl)-cyclohexanecarbonitrile (0.500 g, 2.17 mmol, as prepared in the previous step) in EtOH (6 mL) and water (6 mL) was treated with NH 4 Cl 10 (1.16 g, 21.7 mmol) and Fe powder (606 mg, 10.9 mmol) and heated to 50 *C for 2 h. The cooled mixture was filtered through Celite, and the filter cake was washed with MeOH. The solvents were evaporated in vacuo. The residue was partitioned between water (50 mL) and EtOAc (75 mL), and the layers were separated. The organic layer was dried over MgSO 4 and concentrated in vacuo to afford the title compound (488 mg, 100 %) as an 15 orange oil. The compound was used in the following step without purification. Mass spectrum (ESI, m/z): Caled. for C 1 3
H
16
N
2 , 201.1 (M+H), found 201.3. c) 1-(4-Amino-3-bromo-phenyl)-cyclohexane carbonitrile Br
NH
2 N| The title compound was prepared from 1-(4-amino-phenyl)-cyclohexane 20 carbonitrile (as prepared in the previous step) by bromination with NBS according to the procedure in Example 4, step (b), replacing CH 3 CN with CH 2
CI
2 . 'H-NMR (CDCl 3 ; 400 MHz): 6 7.49 (d, IH, J = 2.0 Hz), 7.23 (dd, I H, J = 8.4, 2.0 Hz), 6.76 (d, 1H, J= 8.4 Hz), 57 2.16-2.08 (m, 2H), 1.90-1.73 (m, 8H). d) 1-[4-Amino-3-(4,4-dimethyl-cyclohex-1-enyl)-phenyl]-cyclohexanecarbonitrile
SNH
2 N 1,N A solution of 1-(4-amino-3-bromo-phenyl)-cyclohexane carbonitrile (136 mg, 5 0.487 minmol, as prepared in the previous step) in DMF (10 mL) was treated with 4,4 dimethyl-cyclohex-1-enylboronic acid (90.0 mg, 0.585 mmol) and Na 2
CO
3 (1.95 mL, 3.90 mmol, 2 M aq). The mixture was degassed via sonication, placed under Ar, treated with Pd(dppfCl 2 (35.6 mg, 0.0487 mmol), and heated to 80 'C overnight. The cooled mixture was partitioned between EtOAc (50 mL) and water (50 mL). The aqueous layer was 10 extracted with EtOAc (2 x 50 mL). The combined organic layers was dried over MgSO 4 and concentrated in vacuo. Silica gel chromatography of the residue on a 20-g Isolute SPE column with 10-15 % EtOAc-hexane afforded the title compound (45.9 mg, 30 %) as a colorless glassy solid. Mass spectrum (ESI, m/z): Calcd. for C 2 1
H
2 8N 2 , 309.2 (M+H), found 309.2. 15 e) 4-Cyano-1-(2-trimnethylsianyIl-etIoxymetIy)-1H-imidazole-2-carboxylic acid [4-(1 cyano-cyclohexyl)-2-(4,4-dimethyl-cyclohex-1-enyl)-phenyl]-aimide N H N NN N 0 o 0 ) 58 The title compound was prepared from 1-[4-amino-3-(4,4-dimethyl-cyclohex-1 enyl)-phenyl]-cyclohexanecarbonitrile (as prepared in the previous step) and 4-cyano-1-(2 trimethylsilanyl-ethoxymethyl)- 1 H-imidazole-2-carboxylate potassium salt (as prepared in Example 1, step (d)) according to the procedure of Example 1, step (f). Mass spectrum 5 (ESL nz): Calcd. for C 3 2
H
43
N
5
O
2 Si, 558.3 (M+H), found 557.8. f) 4-Cyano-JH-intidazole-2-carboxylic acid [4-(1-cyano-cyclohex yl)-2-(4,4-dinmethyl cyclohex-1-enyl)-phenylJ-antide A solution of 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2 carboxylic acid [4-(1-cyano-cyclohexyl)-2-(4,4-dimethyl-cyclohex-1-enyl)-phenyl]-amide 10 (66.0 mg, 0.118 mmol, as prepared in the previous step) in CH 2 Cl 2 (6 mL) was treated with EtOH (3 drops) and TFA (0.8 mL) at RT for 2 h. Solvents were evaporated in vacuo. Purification of the residue by RP-HPLC (C 18) with 20-80 % CH 3 CN in 0.1 % TFA/H 2 0 over 25 min afforded the title compound (25.7 mg, 43 %) as a white solid. 'H-NMR
(CD
3 0D; 400 MHz): 6 8.20 (d, 1H, J = 8.8 Hz), 7.93 (s, IH), 7.37 (dd, IH, J = 8.8, 2.0 15 Hz), 7.26 (d, 1H, J= 2.0 Hz), 5.73-5.67 (m, 1H), 2.29-2.21 (i, 2H), 2.08-1.98 (m, 4H), 1.88-1.68 (m, 6H), 1.58-1.50 (n, 2H), 1.02 (s, 6H). Mass spectrum (ESI, m/z): Calcd. for
C
26
H
2 9
N
5 0, 428.2 (M+H), found 428.2. Example 15 1-[4-[(4-Cyano-1H-inidazole-2-carbony)-aminoJ-3-(4,4-dimethyl-cyclohex-1-enyl) 20 phienyl]-cyclopentanecarboxylic acid N H N N I HO O H a) 1-(4-Nitro-phenyl)-cyclopentanecarbonitrile 59
NO
2 N | The title compound is prepared from 4-(nitro-phenyl)-acetonitrile and 1,4-dibromo butane according to the procedure in Example 14, step (a). 5 b) 1-(4-Nitro-phenyl)-cyclopentanecarboxylic acid
NO
2 HO A solution of 1-(4-nitro-phenyt)-cyclopentanecarbonitrile (as prepared in the previous step) cone H 2 S0 4 is heated at 100 'C for 2 h. The mixture is poured into water and extracted with EtOAc. The organic layer is dried (MgS04) and concentrated in vacuo. 10 The residue is purified by silica gel chromatography with the appropriate solvent to afford the title compound. c) 1-(4-Nitro-phenyl)-cyclopentanecarboxylic acid tert-butyl ester
NO
2 15 A solution of 1-(4-nitro-phenyl)-cyclopentanecarboxylic acid (as prepared in the previous step) in THF at -78 *C in a pressure bottle is treated with 2 drops of concentrated sulfuric acid, and isobutylene gas is condensed into the mixture. The mixture is stirred 24 h at RT, cooled to -78 'C and quenched with satd aq NaHCO 3 . The mixture is warmed to RT and extracted with EtOAc. The organic layer is dried (MgSO 4 ) and concentrated in vacuo. 20 The residue is purified by silica gel chromatography with an appropriate solvent to afford the title compound. d) 1-[4-[(4-Cyano-JH-imnidazole-2-carbonyl)-amino-3-(4,4-dimnethyl-cyclohex-1-enyl) phenyl]-cyclopentanecarboxylic acid 60 The title compound is prepared from 1-(4-nitro-phenyl)-cyclopentanecarboxylic acid tert-butyl ester (as prepared in the previous step) according to the procedures in Example 4 step (a) and Example 1, steps (e)-(g). 5 The following examples are produced according to procedures of previous examples with the corresponding reagents as indicated in the table below: Reagents Ex- Name Structure Procedure ample Reference No. 4-Cyano-IH-midazole-2- H 0 Ex. 14, OH N 16 carboxylik acid [2- step (a); B cyclohex-1-enyl-4-(cis-4- N Example hydroxy-1-isocyano- 4, steps B(OH)2 cyclohexyl)-phenyljamide NC (a), (b) OH and Ex. 1, steps (e) (g) 17 4-Cyano-4-[4-[(4-cyano- H 0 Ex. 14, 1H-imidazole-2-carbonyl)-- N Itp() N amninoj-3-(4,4-dimnethyl- NC IExample cyclohex-J-enyl)-phenyl]- 4, steps cyclohexane carboxylic CN (a), (b) acid methyl ester 0 and Example 1, steps (e)-(g) 61 Example 18 4-[4-[(5-Cyano-1H-imidazole-2-carbonyl)-amino]-3-(4,4-dimethyl-cyclohex-1-enyl) phenyl-cyclohexanecarboxylic acid CN H HN N HOOC 5 a) 4-[4-[(4-Cyano-1H-imidazole-2-carbonyl)-aminoJ-3-(4,4-dimethyl-cyclohex-1-enyl) phenyl]-cyclohexanecarboxylic acid methyl ester CN H N N MeO 2 C 10 The title compound is prepared by deoxygenation of 4-[4-[(4-cyano-IH-imidazole 2-carbonyl)-amino]-3-(4,4-dimethyl-cyclohex-1 -enyl)-phenyl]-cis-4-hydroxy cyclohexanecarboxylic acid methyl ester (as prepared from 4-oxo cyclohexanecarboxylic acid methyl ester using the procedure in Example 2, step (a)) according to the procedure of Dolan, S., et al, .J. Chein., Soc., Chem. Connun., 1588-9 15 (1985). b) 5-Cyano-1H-imidazole-2-carboxylic acid [2-(4,4-dimethyl-cyclohex-1-enyl)-4-(2 moipholin-4-yl-etIyl)-phenyl]-amide hydrochloride The title compound is prepared from 4-[4- f[4-cyano- 1 -(2-trimethylsilanyl 20 ethoxymethyl)- I H-imidazole-2-carbonyl]-amino} -3 -(4,4-dimethyl-cyclohex- 1 -enyl) phenyl]-cyclohexanecarboxylic acid methyl ester (as prepared in the previous step) according to the procedure in Example 2, step (b). 62 Example 19 5-Cyano-1H-iiidazole-2-carboxylic acid [2-(4,4-dimetlyl-cyclohex-1-enyl)-4-(1 iydroxy-4,4-dimethoxy-cyclohexyl)-phenyl]-amide CN H HN OH N N OHO MeO 5 MeO The title compound is prepared from 4,4-dimethoxycyclohexanone (Tetrahedron Lett., 1107-8 (1975) and ibid, 31, 3237-40 (1990)) using the procedure of Example 1, step (h). 10 Example 20 5-Cyano-1H-imidazole-2-carboxylic acid [4-(4,4-dimethoxy-cyclohexyl)-2-(4,4-dimethyl cyclohex-1-enyl)-phenyl]-amide CN H HN N AN 0 MeO MeO 15 The title compound is prepared from 5-cyano-IH-imidazole-2-carboxylic acid [2 (4,4-dimethyl-cyclohex-1-enyl)-4-(1-hydroxy-4,4-dimethoxy-cyclohexyl)-phenyl]-amide (as prepared in Example 19) using the procedure of Example 18 step (a). 63 Example 21 5-Cyano-1H-iiidazole-2-carboxylic acid f2-(4,4-dimetzyl-cyclahex-1-enyi)-4-(1 lzydroxy-4-oxo-cyclohexyl)-phenyl]-amide CN H HN N OH O 5 The title compound is prepared from 5-cyano-1H-imidazole-2-carboxylic acid [2 (4,4-dimethyl-cyclohex-1 -enyl)-4-(1 -hydroxy-4,4-dimethoxy-cyclohexyl)-phenyl]-amide (as prepared in Example 19) by treatment with LiBF 4 in wet CH 3 CN using the procedure of Lipshutz, B. and Harvey, D., Synth. Comnmun., 12, 267 (1982). 10 Example 22 5-Cyano-1H-imidazole-2-carboxylic acid [444-(dimetiylamino-1-hydroxy-cyclohexyl)-2 (4,4-dim ethyl-cyclohex-I-enyl)-phenyl]-amide CN H HN N N OH O N0 15 The title compound is prepared from 5-cyano-IH-imidazole-2-carboxylic acid [2 (4,4-dimethyl-cyclohex-1-enyl)-4-(I-hydroxy-4-oxo-cyclohexyl)-phenyl]-anide (as prepared in Example 21) and dimethylamine (solution in THF) using NaBH(OAc) 3 according to literature procedure (J. Org. Chem., 61, 3849-62 (1996)). 20 64 Example 23 5-Cyano-1H-imidazole-2-carboxylic acid [2-(4,4-dimeityl-cyclohex-1-enyl)-4-(4-oxo cyclohexyl)-pheny]-amide CN H HN N 0X 0 5 a) 4-(4-Nitiro-phienyl)-cyclohexanone
NO
2 0 Concentrated H 2 SO4 (20 mL) was cooled to 0 *C and treated with 4-phenyl cyclohexanone (4.22 g, 24.2 mmol), and fuming nitric acid (1.6 mL) was added very 10 carefully dropwise, keeping the temperature of the mixture below 20 'C. After the addition of nitric acid was complete, the mixture was warmed to RT and allowed to stir for 5 h. The mixture was poured over ice (200 mL) and extracted with EtOAc (3 x 150 mL). The combined organic layers were dried over MgSO 4 and concentrated in vacuo. Silica gel chromatography with 10 % EtOAc-hexane on a 70-g Isolute SPE column (FlashMaster 15 system) afforded the title compound (0.512 g, 10%) as a pale yellow solid. 1 H-NMR (CD30D; 400 MHz): 8 8.20 (d, 2H, J = 8.8 Hz), 7.42 (d, 2H, J = 8.8 Hz), 3.16 (tt, 1H, J= 12.0, 4.0 Hz), 2.58-2.51 (m, 4H), 2.31-2.21 (m, 2H), 2.05-1.91 (m, 2H). b) 4-(4-Ainino-phIenyl)-cyclohexaione N H 2 20 A solution of 4-(4-nitro-phenyl)-cyclohexanone (0.512 g, 2.34 mmol, as prepared in the previous step) in EtOH (50 mL) was hydrogenated under the following conditions 65 on an H-cube apparatus fitted with a 30 mm CatCartTM 5 % Pd/C cartridge: 40 'C, 40 bar H2, flow rate I mL/min. The solvent was evaporated in vacuo. Silica gel chromatography of the residue with 25 % EtOAc-hexane on a 20-g Isolute SPE column (FlashMaster system) afforded the title compound (0.140 g, 32 %) as a colorless glassy solid. Mass 5 spectrum (ESI, m/z): Caled. for C12HisNO, 190.1 (M+H), found 190.2. c) 4-(4-A mino-3-bromo-phenyl)-cyclohexaione Br
NH
2 0 The title compound was prepared from 4-(4-amino-phenyt)-cyclohexanone (as prepared in the previous step) by bromination with NBS according to the procedure in 10 Example 4, step (b), replacing CH 3 CN with CH 2
C
2 . Mass spectrum (ESI, n/z): Caled. for C 1 2
H
4 NOBr, 268.0/270.0 (M+H), found 268.3/270.2. d) 4-[4-Amino-3-(4,4-diiethyl-cyclohex-1-enyl)-phenyl]-cyclohexanone C, N H 2 The title compound was prepared from 4-(4-amino-3-bromo-phenyl) 15 cyclohexanone (as prepared in the previous step) according to the procedure in Example 1, step (e). Mass spectrum (ESI, m/z): Caled. for C2 0
H
2 7 NO, 298.2 (M+H), found 298.2. e) 4-Cyano-I-(2-triietlzylsilanyl-etioxymetlzyl)-1H-imidazole-2-carboxylic acid [2-(4,4 diiethyl-cyclohex-1-enyl)-4-(4-oxo-cyclohexyl)-phenyl]-anide 66 N HN N N 0J zSi, The title compound was prepared from 4-[4-amino-3-(4,4-dimethyl-cyclohex-1 enyl)-phenyl]-cyclohexanone (as prepared in the previous step) and 4-cyano-1-(2 trimethylsilanyl-ethoxymethyl)-i H-imidazole-2-carboxylate potassium salt (as prepared in 5 Example 1, step (d)) according to the procedure in Example 1, step (f). Mass spectrum (APCI, m/z): Calcd. for C 31
H
42
N
4
O
3 Si, 547.3 (M+H), found 547.0. f) 4-Cyano-1H-iimidazole-2-carboxylic acid [2-(4,4-diimetlyl-cyclohex-1-enyl)-4-(4-oxo cyclohexyl)-phenyll-amide The title compound was prepared from 4-cyano-1-(2-trimethylsilanyl 10 ethoxymethyl)-1H-imidazole-2-carboxylic acid [2-(4,4-dimethyl-cyclohex-1-enyl)-4-(4 oxo-cyclohexyl)-phenyl]-amide (as prepared in the previous step) according to the procedure in Example 1, step (g). 'H-NMR (CDCl 3 ; 400 MHz): 6 9.59 (s, 1H), 8.31 (d, 1H, J = 8.4 Hz), 7.72 (s, 1H), 7.20 (dd, 1H, J = 8.4, 2.0 Hz), 7.08 (d, IH, J = 2.0 Hz), 5.81 5.75 (m, 1H), 3.04 (tt, IH, J = 11.6 Hz, 4.0 Hz), 2.56-2.48 (m, 4H), 2.33-2.19 (m, 4H), 15 2.14-2.08 (m, 2H), 2.04-1.91 (2H), 1.62-1.55 (m, 2H), 1.11 (s, 6H). Mass spectrum (APCI, m/z): Caled. for C 31
H
42 N40 3 , 417.2 (M+H), found 417.2. Example 24 4-Cyano-1H-iimidazole-2-carboxylic acid [4-(4-diethylamnino-cyclohexyl)-2-(4,4 20 dimethyl-cyclohex-1-enyl)-phenyl]-amnide 67 N N H N A~ 0 N The title compound is prepared from 4-cyano-1H-imidazole-2-carboxylic acid [2 (4,4-dimethyl-cyclohex-1-enyl)-4-(4-oxo-cyclohexyl)-phenyl]-amide (as prepared in 5 Example 23) and diethylamine using NaBH(OAc)3 according to literature procedure (J. Org. Chem., 61, 3849-62 (1996)). The following examples are produced according to procedures of previous examples with the corresponding reagents as indicated in the table below: 10 Ex- Name Structure Procedure Reagents ample Reference No. 4-Cyano-JH-imidazole-2- H 0 25 carboxylic acid [2-(4,4- N NH Example N dimnethyl-cyclohiex-1-enyl)- NC |I , step (h) 4-(3-hydroxy- A H Organic bicyclo[3. 2. 1]oct-3-yl)- Syntheses, 51 phenyl]-amide 60-5 (1971) 68 4-Cyano-JH-imidazole-2- H 0 26 carboxylic acid (2-(4,4- N NH Example H NN O dimethyl-cyclohex-1-enyl)- N 22 NC 4- 1 -hydroxy-4-[(2 methoxy-ethyl)-methyl amino]-cyclohexyl} phenyl)-amide O 4-Cyano-1H-inidazole-2- 0 27 carboxylic acid [2-(4,4- N NH Example H N dimethyl-cyclohex-I-eny)- NC 24 4-(4-meorpholin-4-yl cyclohexyl)]-phenyj-ai ide CN 0 4-Cyano-JH-iinidazole-2- H 0 28 carboxylic acid (2-44,4- N NH Example diinetlyl-cyclohex-1-enyl)- \N 24 H N 69 4-Cyano-1H-imidazole-2- H 0 29 carboxylic acid {2-(4,4- NH Example N dimethyl-cyclohex-1-enyl)- N 24 H 4-[4-(4-ethyl-piperazin-1 0 -y)-cyclohexyl]-phenyl} amide N N 4-Cyanzo-1H-imzidazole-2- 0 30 carboxylic acid (2-(4,4- N NH Example H dimethyl-cyclohex-1-enyl)- N 24 4-{4-[(2-mehoxy-ethy)- NC (Fluorochem, methyl-amino]- Inc.) cyclohexyl}-phenyl)-amide 4-Cyano-1H-imidazole-2- H 31 carboxylic acid (2-(4,4- N NH Example N H 2 N~r dimethyl-cyclohex-1-enyl)- N 24 4-[4-(2-ethoxy- (Pfaltz and ethy1amio)-cyclohexyl]- Bauer phenyl}-amide Chemicals, Inc.) HNO 4-Cyano-1H-imidazole-2- H 0 32 carboxylic acid [4-{4-Jbis- N NH Example OH H OH N N (2-hydroxy-eityl)-amino]- NC 24 cyclohexyl]-2-(4,4 dimethyl-cyclohex-J-enyl) pheuyll-amide HO N- OH 70 4-Cyano-1H-inidazole-2- H 0 33 carboxylic acid (2-(4,4- NH Example dim etlyl-cyclolzex-1-enyl)- NC24 H 2 NN So 2 Me NC I--S0m 4-[4-(2-nethanesulfonyl ethylaino)-cyclohexyl]- (Apollo phenyl}-aide Scientific, Inc.) HN SO2Me 4-Cyano-H-imnidazole-2- H 0 34 carboxylic acid [4-[4- N NH Example 0 \N H2N-" (diiethylcarbamoylimethyl NC N 24 N NC I -amino)-cyclohexyl]-2- (WO (4,4-dimethyl-cyclohex-1- 2001025234 enyl)-phenyl]-amide 0 HN N A1) Example 35 4-Cyano-IH-imidazole-2-carboxylic acid (2-(4,4-dimetlyl-cyclohex-1-enyl)-6-[1-(4 5 ethyl-piperazin-1-yl)-cyclopentyl]-pyridin-3-yl}-amide N H N EtN N N 11 0 H a) 6-Broimo-2-iodo-pyridin-3-ylamine Br NH 2 10 71 To a stirred solution of 6-bromo-pyridin-3-ylamine (10.2 g, 0.0580 mol) and Ag 2
SO
4 (18.1 g, 0.0580 mol) in EtOH (150 mL) was added 12 (7.59 g, 0.0580 mol) and the reaction was allowed to stir overnight. At this time hexane (200 mL) was added and the resultant mixture was filtered through Celite. The solvent was removed in vacuo, dissolved 5 in CHC1 3 (200 mL), washed with aqueous saturated Na 2
S
2 0 3 (100 mL), water (1 x 100 mL), and dried (Na 2 SO4). The solvent was concentrated in vacuo and the residue was dissolved in hot EtOAc (100 mL), filtered and treated with hexanes (100 mL). Filtration gave 11.2 g (65 %) of 6-bromo-2-iodo-pyridin-3-ylamine as a white crystalline material. 'H- NMR (CDCl 3 ; 400 MHz): 8 7.10 (d, IH, J = 8.2 Hz), 6.74 (d, IH, J = 8.2 Hz), 4.06 (br 10 s, 2H). b) 6-Bromno-2-(4,4-dimetlyl-cyclohex-1-enyl)-pyridin-3-ylaimine
NH
2 N Br A solution of 6-bromo-2-iodo-pyridin-3-ylamine (as prepared in the previous step, 1.00 g, 3.35 mmol) in toluene (27 mL) and EtOH (13.5 mL) was treated with 2.0 M aq 15 Na 2
CO
3 (13.4 mL, 26.8 mmol) and 4,4-dimethyl-cyelohex-1-enylboronic acid (567 mg, 3.68 mmol). The mixture was degassed via sonication, placed under Ar, treated with Pd(PPh 3
)
4 (271 mg, 0.234 mmol), and heated to 80 'C for 5 h. The cooled mixture was diluted with EtOAc (100 niL) and washed with water (2 x 50 mL). The combined aqueous layers were extracted with EtOAc (1 x 100 mL). The combined organic layers were dried 20 over MgSO 4 and concentrated in vacuo. Silica gel chromatography of the residue on a Varian MegaBond Elut 50-g column with 10 % EtOAc-hexane afforded 668 mg (71 %) of 6-bromo-2-(4,4-dimethyl-cyclohex-1-enyl)-pyridin-3-ylamine as a tan solid. 1 H-NMR (CDCl 3 ; 400 MHz): 6 7.06 (d, 1H, J = 8.3 Hz), 6.85 (d, 1H, J = 8.3 Hz), 5.95 (m, IH), 3.86 (br s, 2H), 2.43-2.39 (m, 2H), 1.99-1.97 (in, 2H), 1.51 (t, 2H, J = 6.4 Hz), 0.99 (s, 6H). 25 c) 4-Cyano-1-(2-timnethylsilanyl-ethoxyimetlzyl)-H-iimidazole-2-carboxylic acid [6 bromno-2-(4,4-dimetlhyl-cyclohex-1-enyl)-pyridin-3-yl]-aiide 72 CN H N N N N BO SEM Br0 The title compound was prepared from 6-bromo-2-(4,4-dimethyl-cyclohex- 1 -enyl) pyridin-3-ylamine (as prepared in the previous step, 60 mg, 0.21 mmol), potassium 4 5 cyano-1 -(2-trimethylsilanyl-ethoxymethyl)-IH-imidazole-2-carboxylate (as prepared in Example 1, step (d), 91.0 mg, 0.290 mmol), PyBroP (157 mg, 0.330 mmol) and DIEA (91.0 pL, 0.520 mmol) according to the procedure in Example 1, step (f) (84 mg, 78 %). 'H-NMR (CDCl 3 ; 400 MHz): 6 9.91 (s, 1H), 8.64 (d, 1H, J = 8.6 Hz), 7.79 (s, 1H), 7.38 (d, 1H, J = 8.6 Hz), 6.00 (m, lH), 5.92 (s, 2H), 3.67 (m, 2H), 2.46 (m, 2H), 2.14 (m, 2H), 1.62 10 (t, 2H, J =6.3 Hz), 1.12 (s, 6H), 0.98 (m, 2H). di) 5-Cyaio-H-imidazole-2-carboxylic acid [6-brom o-2-(4,4-dimetIyl-cyclohex-1-enyl) pyridin-3-yl]-amide H N N Br o H The title compound was prepared from 4-cyano-1-(2-trimethylsilanyl 15 ethoxymethyl)-1H-imidazole-2-carboxylic acid [6-bromo-2-(4,4-dimethyl-cyclohex-1 enyl)-pyridin-3-yl]-amide (as prepared in the previous step) according to the procedure in Example 1, step (g). 'H-NMR (CD 3 0D; 400 MHz): 8 8.53 (d, 1H, J = 8.8 Hz), 8.03 (s, IH), 7.48 (d, 1H, J = 8.8 Hz), 6.04-5.99 (m, IH), 2.48-2.40 (m, 2H), 2.13-2.08 (m, 2H), 1.61 (t, 2H, J= 6.0 Hz), 1.09 (s, 6H). Mass spectrum (ESI, m/z): Calcd. for C 18 Hi 8 BrN 5 O, 20 400.1 (M+H), found 400.0. e) 4-Cyano-1H-imidazole-2-carboxylic acid [2-(4,4-dimetlyl-cyclohex-1-enyl)-6-(1 iydroxy-cyclopentyl)-pyridin-3-ylJ-aimide 73 N H N N N HO O H The title compound is prepared from 5-cyano-IH-imidazole-2-carboxylic acid [6 bromo-2-(4,4-dimethyl-cyclohex- 1-enyl)-pyridin-3-yl]-amide (as prepare d in the previous 5 step) and cyclopentanone according to the procedure in Example 1, step (h). f) 4-Cyano-1H-imidazole-2-carboxylic acid f2-(4,4-dimetlyl-cyclohex-J-enyl)-4-[1-(4 ettyl-piperazin-1-yl)-cyclopentyl]-phenyl}-amide The title compound is prepared from 4-cyano-1H-imidazole-2-carboxylic acid [2 (4,4-dimethyl-cyelohex-1-enyl)-6-(1-hydroxy-cyclopentyl)-pyridin-3-yl]-amide (as 10 prepared in the previous step), N-ethylpiperazine, and thionyl chloride in DCM solvent according to the procedure in Example 43. Example 36 4-Cyano-JH-imidazole-2-carboxylic acid {2-(4,4-dimethyl-cyclohex-1-enyl)-6-[1-(2 pyrrolidin-1-yl-ethoxy)-cyclopentyl]-pyridin-3-yl}-amide H 0 N NH N NC -N oNo 15 The title compound is prepared using 4-cyano-1H-imidazole-2-carboxylic acid [2 (4,4-dimethyl-cyclohex-1-enyl)-4-(1-hydroxy-cyclopentyl)-phenyl]-amide (as prepared in Example 3) and 2-pyrrolidin-1-yl-ethanol according to the procedure of Example 43, except replacing the SOC 2 with 10 equivalents of trifluoroacetic acid and heating in a 20 sealed tube at 50 'C for 8 h. 74 The following example is produced according to the procedures of previous examples with the corresponding reagents as indicated in the table below: Ex- Name Structure Procedure Reagents ample Reference No. 4-Cyano-JH-uidazole-2- H 0 carboxylic acid {6-[1-(4- N NH Ex.35 N nethyl-piperazin-1-yl) cyclopentyl]-2- B 0 spiroj4.5Jdec-7-en-8-yl- N NMe pyridin-3-yl}-amide W0200506370 5 Me N N H 5 The following examples are produced according to procedures of previous examples with the corresponding reagents as indicated in the table below: 75 Ex- Name Structure Procedure Reagents ample Reference No. 4-[4-[(4-Cyano-1H- H O 38 pyrrole-2-carbonyl)- N H Example H amino]-3-(4,4-dinethy!- NC 1, step (f); N O cyclohex-1-enyl)-phenyq]- Example 2 cis-4-hydroxy- (Canadian J. cyclohexanecarboxylic Chem. 59, 2673 acid COOH (1981)) 4-[4-[(4-Cyano-JH- H 0 39 pyrrole-2-carbonyl)- NH Example H aminoJ-3-(4,4-dnethyN 1, step (f); N / cyclohex-1-enyl)-phenyl]- Bxample cyclohexanecarboxylic 18 (Canadian J. acid Chen. 59, 2673 COOH (1981)) 4-Cyano-JH-imidazole-2- H 0
NH
2 40 carboxylic acid [4-[4-(4- N NH N Example N methyl-piperazin-1-yl)- N N 1, steps NCI cyclohexylJ-2-(4-methyl- (f)-(g); Br (WO piperidin-1-yl)-phenyl]- Example 2005131022, aide 23; Example A N 24 MeO OMe Tetrahedron Lett., 31, 3237 76 40 (1990)); 4-methyl piperazine 4-Cyano-1H-imidazole-2- H 0 Example NH 2 41 carboxylic acid [2-(4- NH 1, steps N methyl-piperidin-1-yl)-4- N N (f(g A NC IEape B (4-morpholin-4-yl- Example Br(WO cyclohexyl)-phenyl]-amide 23; 2005131022, Example Al); 24 MeO OMe Tetrahedron Lett., 31, 3237 40 (1990)); morpholine 4-Cyano-JH-inidazole-2- H 0 Example NH 2 42 carboxylic acid [4-{4-[(2- N NH 1, steps N inethoxy-ethyl)-methyl- N NC amino]-cyclohexyl}-2-(4- Example Br (WO methyl-piperidin-1-yl)- 23; 2005131022, phenyll-amide Example Al); 24 0 MeO OMe Tetrahedron Lett., 31, 3237 40 77 (1990)); H NO (Fluorochem, Inc.) Example 43 4-Cyano-1H-imidazole-2-carboxylic acid {2-(4,4-dimethlyl-cyclohex-1-enyl)-4-[1-(2 methoxy-ethylamino)-cyclohexyl]-phenyl}-amide 5 H Ns \CN N HHN H NI N 0 N C N 0 To a suspension of 4-cyano-lH-imidazole-2-carboxylic acid [2-(4,4-dimethyl cyclohex-1-enyl)-4-(1-hydroxy-cyclohexyl)-phenyl]-amide (as prepared in Example 1, 42.0 mg, 0.100 mmol) in 1.5 mL of DCM at -15 C was added SOC 2 (22.0 gL, 0.300 10 mmol) under Ar. After stirring at RT for 1 h, the mixture was cooled to -15 *C. To the reaction was then added 2-methoxyethylamine (70.0 pL, 0.800 mmol) and the resulting mixture was stirred at RT for 2 h. The mixture was diluted with EtOAc (30 mL) and washed with H 2 0 (2 x 10 mL) and brine (10 mL). After drying over Na 2
SO
4 and concentrating in vacuo, the residue was purified by silica gel chromatography (1-5 % 15 MeOH/DCM) to afford the title compound (21.7 mug, 46 %) as a white solid. 'H-NMR (1:1 CDCI 3
/CD
3 0D; 400 MHz): 5 8.40 (d, 1H, J = 8.6 Hz), 7.79 (s, 1H), 7.44 (m, 1H), 7.32 (br s, 1H), 5.81 (m, 1 H), 3.48 (t, 2H, J = 5.1 Hz), 3.27 (s, 3H), 2.60 (t, 2H, J = 5.1 Hz), 2.35-2.45 (m, 2H), 2.28-2.35 (m, 2H), 2.09-2.15 (m, 2H), 1.87-1.98 (m, 2H), 1.68 1.78 (m, 2H), 1.61 (t, 2H, J = 6.3 Hz), 1.34-1.60 (m, 4H), 1.12 (s, 6H). Mass spectrum 20 (APCI-neg, m/z): Calcd. for C 2 8HnNSO2, 474.3 (M-H), found 474.5. 78 Examples 44 and 45 4-Cyano-1H-imidazole-2-carboxylic acid [2-(4,4-dimethyl-cyclohex-1-enyl)-4-(cis-1 iydroxy-cis-4-norpholin-4-yl-cyclohexyl)-phenyl]-amide (44) and 4-Cyano-IH imidazole-2-carboxylic acid [2-(4,4-dizetlzyl-cyclohex-1-enyl)-4-(cis-1-lhydroxy-trans-4 5 morpholin-4-yl-cyclohexyl)-phenylj-amide (45) H HN C H H CN N ON N HO I _r HO 11 r 0 and 0 N N 0 0 44 45 a) 4-(1,4-Dioxa-spiro[4.5]dec-8-y)-iorpholine hydrochloride 0_ N 0 HCI 10 A solution of 1,4-dioxa-spiro[4.5]decan-8-one (5.00 g, 32.0 mmol) in
CH
2 Cl 2 (100 mL) was treated with morpholine (2.79 mL, 32.0 mmol), NaBH(OAc) 3 (9.50 g, 44.8 mmol), and acetic acid (1.84 mL, 32.0 mmol) at RT for 4 h. The mixture was quenched with NaOH (75 mL, 2N aq) and extracted with ether (3 x 150 mL). The combined organic layers were washed with water (1 x 100 mL) and brine (1 x 100 mL), 15 dried over MgSO 4 , and concentrated in vacuo to about 100 mL volume. HCl (9 m.L, 4N in dioxane) was added dropwise with stirring. The resulting precipitate was filtered, rinsed with ether, and air-dried to afford the title compound (6.79 g, 80 %) as a white solid. 'H NMR (CD 3 0D; 400 MHz): 6 4.13-4.05 (m, 2H), 3.90-3.80 (m, 2H), 3.54-3.46 (in, 2H), 3.32-3.17 (m, 3H), 2.23-2.14 (m, 2H), 1.95-1.75 (m, 4H), 1.72-1.61 (m, 2H). 79 b) 4-Morpholin-4-yl-cyclohexanone N 0,, A suspension of 4-(1,4-dioxa-spiro[4.5]dec-8-yI)-morpholine hydrochloride (6.79 g, 25.7 mmol, as prepared in the previous step) in THF (100 mL) was treated with 5 HC1 (38.6 mL, 77.2 mmol, 2M aq) and heated to 80 *C for 4 h. The cooled mixture was treated with satd aq NaHCO 3 to pH 7 and extracted with ether (3 x 250 mL). The combined organic layers were dried over MgSO 4 and concentrated in vacuo to afford the title compound (2.22 g, 47 %) as a colorless oil. 1 H-NMR (CDCl 3 ; 400 MHz): 5 3,78-3.72 (m, 4H), 2.60-2.55 (m, 4H), 2.36-2.25 (m, 2H), 2.09-1.99 (m, 2H), 1.93-1.82 (m, 2H). 10 c) 4-Cyano-1H-imidazole-2-carboxylic acid [2-(4,4-diimethyl-cyclohex-1-enyl)-4 (cis-1-hydroxy-cis-4-morpholin-4-yl-cyclohexyl)-phenyl]-amide (44) and 4-Cyano-IH imidazole-2-carboxylic acid [2-(4,4-dimethyl-cyclohex-1-enyl)-4-(cis-1-hydroxy-trans-4 morpholin-4-yl-cyclohexyl)-phienyl]-amnide (45) The title compounds were prepared from 4-cyano-1H-inidazole-2-carboxylic acid 15 [4-bromo-2-(4,4-dimethyl-cyclohex-1-enyl)-phenyl]-amide (as prepared in Example 1, step (g)) and 4-morpholin-4-yl-cyclohexanone (as prepared in the previous step) according to the procedure as described in Example 22. 44: 'H-NMR (CD 3 0D; 400 MHz): 6 8.12 (d, 1H, J = 8.6 Hz), 7.93 (s, 1H), 7,39 (dd, 1H, J = 8.6, 2.3 Hz), 7.34 (d, 1H, J= 2.3 Hz), 5.73 (in, 1H), 3.72-3.74 (m, 4H), 2.69 (m, 4H), 20 2.43 (t, IH, J= 6.4 Hz), 2.26-2.34 (m, 2H), 2.07 (m, 2H), 1.77-1.92 (m, 8H), 1.59 (t, 2H, J = 6.3 Hz), 1.07 (s, 6H). Mass spectrum (ESI, m/z): Calcd. for C 2 9
H
37
N
5 0 3 , 504.3 (M+H), found 504.2. 45: 'H-NMR (CD 3 0D; 400 MHz): 6 8.20 (d, 1H, J = 8.6 Hz), 7.97 (s, IH), 7.45 (dd, 1H, J = 8.6, 2.3 Hz), 7.36 (d, 1H, J= 2.3 Hz), 5.74 (in, IH), 3.69 (m, 4H), 2.54 (m, 4H), 2.36 25 2.45 (m, 2H), 2.28-2.36 (m, 3H), 2.08 (m, 2H), 1.92-2.02 (m, 2H), 1.48-1.69 (m, 6H), 1.09 (s, 6H). Mass spectrum (ESI, m/z): Calcd. for C 2 9
H
3 7
N
5 0 3 , 504.3 (M+H), found 504.3. 80 IV. Results Fluorescence Polarization Competition Immunoassay An autophosphorylation, fluorescence polarization competition immunoassay was 5 used to determine the potency for c-fins inhibition exhibited by selected compounds of Formula 1. The assay was performed in black 96-well microplates (LJL BioSystems). The assay buffer used was 100 mVi 4-(2-hydroxyethyl)piperazine 1-ethanesulfonic acid (HEPES), pH 7.5, 1 mM 1,4-dithio-DL-threitol (DTT), 0.01 % (v/v) Tween-20. Compounds were diluted in assay buffer containing 4 % dimethylsulfoxide (DMSO) just 10 prior to the assay. To each well, 5 pL of compound were added followed by the addition of 3 pL of a mix containing 33 nM c-fins (Johnson & Johnson PRD) and 16.7 mlM MgC 2 (Sigma) in assay buffer. The kinase reaction was initiated by adding 2 sL of 5 mM ATP (Sigma) in assay buffer. The final concentrations in the assay were 10 nM c-fins, 1 mM ATP, 5 mM MgC 2 , 2 % DMSO. Control reactions were ran in each plate: in positive and 15 negative control wells, assay buffer (made 4 % in DMSO) was substituted for the compound; in addition, positive control wells received 1.2 4 of 50 mM ethylenediaminetetraaceticacid (EDTA). The plates were incubated at room temperature for 45 min. At the end of the incubation, the reaction was quenched with 1.2 pL of 50 mM EDTA (EDTA was not 20 added to the positive control wells at this point; see above). Following a 5-min incubation, each well received 10 pL of a 1:1:3 mixture of anti-phosphotyrosine antibody, iOX, PTK green tracer, lOX (vortexed), FP dilution buffer, respectively (all from PanVera, cat. # P2837). The plate was covered, incubated for 30 min at room temperature and the fluorescence polarization was read on the Analyst. The instrument settings were: 485 nm 25 excitation filter; 530 nm emission filter; Z height: middle of well; G factor: 0.93. Under these conditions, the fluorescence polarization values for positive and negative controls were approximately 300 and 150, respectively, and were used to define the 100 % and 0 % inhibition of the c-fins reaction. The reported IC 50 values are averages of three independent measurements. 30 CSF-l-Driven Mouse Bone-Marrow Derived Macrophages Assay 81 Macrophages are derived by culturing mouse bone marrow in alpha-MEM supplemented with 10% FCS and 50 ng/ml recombinant mouse CSF-1 in bacteriologic dishes. On the sixth day, macrophages are detached from dishes, washed, and resuspended to 0.05 million cells/ml in alpha-MEM containing 10% FCS. One hundred ul of cell 5 suspension are distributed per well into 96 well culture plates. Wells are further supplemented with the addition of 50 ul media containing 15 ng/ml CSF-1, 3 uM Indomethacin, and 3X of a dilution series of test compounds. The cells are cultured for 30 hrs at 37 degrees and 5%CO2. During the final six hours, cultures are supplemented with an additional 30 ul of media containing a 1:500 dilution of bromodeoxyuridine (BrDU). 10 At the end of the culture period, the plates are spun at 1000 RPM for 1 minute and 130 ul of media is removed with a pipet and replaced with 150 ul of fixative solution for 1 hour @ room temperature. The fixative is then dispelled from the plates and the plates allowed to air dry. Incorporation of BrDU into the fixed, dried cells is quantified using a specific ELISA. 15 Table 2 lists the assay results for representative compounds of the invention. TABLE 2 Example I nM c-fis; mCSF driven peptide Pi proliferation assay BMDM IC-50 (4M) (Mouse) IC-50 (pM) 1 0.0059 0.072 2 0.00065 0.087 3 0.0023 0.0117 4 0.0095 0.099 14 0.02 0.15 82 27 0.0019 0.016 28 0.00099 0.0102 43 0.0029 0.111 44 0.00072 0.0028 45 0.0034 0.0085 While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come 5 within the scope of the following claims and their equivalents. All publications disclosed in the above specification are hereby incorporated by reference in fll. 83
Claims (13)
1. A method of treating a disorder selected from the group consisting of inflammation, cancer, cardiovascular disease, diseases with an inflammatory component, pain, metastasis, and 5 autoimmune diseases in a mammal comprising administering to the mammal a therapeutically effective amount of at least one compound of Formula I Z NH X J R 2 I 0 or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein: Wis HN HN 4 HN\ HN N-N 4R4 R , or N R4 H wherein each R 4 is independently H, F, Cl, Br, I, OH, OCH 3 , OCH 2 CH 3 , SC( 1 . 4 )alkyl, 15 SOC(i. 4 )alkyl, SO 2 C( 1 . 4 )alkyl, -C( 1 . 3 )alkyl, CO 2 Rd, CONReRf, C-- CRg, or CN; wherein Rd is H, or -C( 1 . 3 )alkyl; Re is H, or -C( 1 . 3 )alkyl; R is H, or -C( 1 . 3 )alkyl; and R9 is H, -CH 2 OH, or -CH 2 CH 2 OH; 20 R 2 is cycloalkyl, spiro-substituted cycloalkenyl, heterocyclyl, spirosubstituted piperidinyl, thiophenyl, dihydrosulfonopyranyl, phenyl, furanyl, tetrahydropyridyl, or - 85 dihydropyranyl, any of which may be independently substituted with one or two of each of the following: chloro, fluoro, hydroxy, C(I1 3 )alkyl, and C(I1 4 )alkyl; Z is H, F, or CH 3 ; 5 J is CH, or N; R 1 RR R 1 R R RY R X is Rz / Rz ! Rz j Rz R z R NR3 0 S Rz Rz Rz Rz wherein R is -C(I1 4 )alkyl, -ORa, -CN, -NA'A 2 , -SO 2 CH 3 , -COORa, -CO 2 CH 3 , -CH 2 -NA A 2 , -CONA A 2 , -CH 2 ORa, -OC(l1 4 )alkylORa, -NHCH 2 CH 2 CO 2 Ra, 0 -NHCH 2 CH 2 ORa, -NWaCH 2 CH 2 NAA 2, -OC(1. 4 )alkylNA'A 2 , -OCH 2 CO 2 Ra, -CH 2 CO 2 Ra, 2 12 12 -CH 2 CH 2 SO 2 C(I1 4 )alkyl, -SO 2 CH 2 CH 2 NA A , -SOCH 2 CH 2 NA A , -SCH 2 CH 2 NA A, -NHSO 2 CH 2 CH 2 NA'A 2 , phenyl, imidazolyl, thiazolyl, 4H-[1,2,4]oxadiazol-5-onyl, 4H-pyrrolo[2,3-b]pyrazinyl, pyridinyl, [1,3,4]oxadiazolyl, 4H-[1,2,4]triazolyl, tetrazolyl, pyrazolyl, [1,3,5]triazinyl, or [1,3,4]thiadiazolyl; 5 Rz and R' are independently H or -C(1. 4 )alkyl, wherein both Rz may have either syn or anti stereochemistry; alternatively both Rz in a syn relationship may be taken together to form -(CH 2 )n 1 -, where n is 2 or 3; 20 R 3 is H, C(1. 4 )alkyl, C(1. 3 )alkyl-CF 3 , CH 2 CH 2 NH 2 , CH 2 CH 2 ORa, -COCH 3 , CONH 2 , or CO 2 R; A' is H, -C(1. 4 )alkyl, or CH 2 CH 2 ORa; A2 is H, -C(1. 4 )alkyl, CORa, CH 2 CON(CH 3 ) 2 , -CH 2 CH 2 ORa, -CH 2 CH 2 SC(1. 4 )alkyl, -CH 2 CH 2 SOC(I1 4 )alkyl, or -CH 2 CH 2 SO 2 C(I1 4 )alkyl; - 86 alternatively, A' and A 2 may be taken together with their attached nitrogen to form a heterocyclic ring selected from the following: Ra Raa Ra Ra Ra Ra Nj- N- Rbb-N N-1- -,S N-- O=S N R Ra O a Raa Ra Ra Ra Ra N-- S N- - Ra N,// ,and Ra wherein Ra is H or C(1. 4 )alkyl; 5 Raa is H or C(1. 4 )alkyl; and Re is H, -C(1. 4 )alkyl, -CH 2 CH 2 0CH 2 CH 2 0CH 3 , -CH 2 CO 2 H, -C(O)C(1. 4 )alkyl, or -CH 2 C(O)C(1. 4 )alkyl.
2. The method of claim 1, wherein the disorder is inflammation. 0
3. The method of claim 1, wherein the disorder is cancer.
4. The method of claim 1, wherein the disorder is a cardiovascular disease. 15 5. The method of claim 1, wherein the disorder is a disease with an inflammatory component selected from the group consisting of glomerulonephritis, inflammatory bowel disease, prosthesis failure, sarcoidosis, congestive obstructive pulmonary disease, idiopathic pulmonary fibrosis, asthma, pancreatitis, HIV infection, psoriasis, diabetes, tumor-related angiogenesis, age-related macular degeneration, diabetic retinopathy, restenosis, schizophrenia 20 and Alzheimer's dementia. - 87 6. The method of claim 1, wherein the disorder is pain selected from the group consisting of skeletal pain caused by tumor metastasis, osteoarthritis, and visceral, inflammatory, and neurogenic pain in a mammal. 5 7. The method of claim 1, wherein the disorder is metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, or hairy cell leukemia.
8. The method of claim 1, wherein the disorder is an autoimmune disease selected from 0 the group consisting of systemic lupus erythematosus, rheumatoid arthritis, other forms of inflammatory arthritis, psoriasis, Sjogren's syndrome, multiple sclerosis, and uveitis.
9. The method of claim 1 wherein in the compound of Formula I, or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, H H Wis HN\ NH 2 H N / N A 0 Is%>S I/>S N O N N , N O0 CI CI HN HN\ HN\ Br CI N\ N HN\N H N /N , N\ N O NJ\ N N 0 1 o - ZN . HN ,or N - 88 R2is OH NN N N N, NNo -1 or -\ Z is H; R 1 RR R 1 R R RY R X is R R Rz Rz S: N, 3 0 S RRz 0 YRz R z or Rz I -12 wherein R is -OH, -CN, -NA'A 2 , -SO 2 CH 3 , -COORa, -CO 2 CH 3 , -CH 2 -NA A, 5 -CONAA 2, -CH 2 ORa, -NHCH 2 CH 2 CO 2 Ra, -NHCH 2 CH 2 ORa, -NHCH 2 CH 2 NA' 2 , -OC(1. 4 )alkylNA'A 2 , -OCH 2 CO 2 Ra, or tetrazolyl; A' is H, or -CH3; A 2 is H, -CH 2 CH 2 0CH 3 , -COCH 3 , or -CH3; 0 alternatively, A' and A 2 may be taken together with their attached nitrogen to form a heterocyclic ring selected from the following: Ra Raa Ra Ra Ra R aO N-J- OX\ Ra N-- RbbN N-1- -S N-|- O=S N aa 7 Ra 7 > 0 > a_ Raa Ra Ra Ra Ra Ra N-/ , and N Ra wherein Ra is H, or -C(1. 4 )alkyl; Raa is H, or -C(1. 4 )alkyl; 15 ReR is H, -C(1. 4 )alkyl, -CH 2 CO 2 H or -COCH 3 ; - 89 RY is H, or -CH3; Rz is H, -CH 3 , or may be taken together as -CH 2 CH 2 -; R 3 is H, -CH 2 CF 3 , -COCH 3 , -CH 3 , -CO 2 CH 3 , -CONH 2 , or -CO 2 H. 5 10. The method of claim 9 wherein in the compound of Formula I, or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, R is 'OND N', or ; R RY R RY R 1 RY R X is RRz Rz Rz -0N, 0 S ~R R 0 Rz Rz Rz 0 1 212 wherein R' is -OH, -CN, -NA'A 2 , -SO 2 CH 3 , -COOH, -CO 2 CH 3 , -CH 2 -NA A, -CONH 2 , -CON(CH 3 ) 2 , -CH 2 OH, -OCH 2 CH 2 N(CH 3 ) 2 , -NHCH 2 CH 2 CO 2 CH 3 , -NHCH 2 CH 2 0CH 3 , -NHCH 2 CH 2 NAA 2, -OC(. 4 )alkylNA'A 2 , -OCH 2 CO 2 H, or tetrazolyl; 15 A' is H, or -CH3; A2 is H, -CH 2 CH 2 0CH 3 , -COCH 3 , or -CH3; alternatively, A' and A 2 may be taken together with their attached nitrogen to form a heterocyclic ring selected from the following: N- - bbN N- - S N-- N- 0\J and N--. 20 - 90 wherein Re is H, -C(. 4 )alkyl, -CH 2 CO 2 H or -COCH 3 ; R' is H, or -CH3; Rz is H, -CH 3 , or may be taken together as -CH 2 CH 2 -; R 3 is H, -CH 2 CF 3 , -COCH 3 , -CH 3 , -CO 2 CH 3 , -CONH 2 , or -CO 2 H. 5
11. The method of claim 10 wherein in the compound of Formula I, or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, W i s N NH N, r H N -\ ~ N or \' R2 is N ,or 0
12. The method of claim 11 wherein in the compound of Formula I, or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, W is HN HN\ ~N ZNo -\ 7N N or R is or Rz R Xis N RzS 0 R [5 Rz ,or - 91 wherein R' is -OH, -NH 2 , -N(CH 3 ) 2 , -SO 2 CH 3 , -COOH, -CO 2 CH 3 , -CH 2 -morpholinyl, -CONH 2 , -CON(CH 3 ) 2 , -CH 2 OH, -OCH 2 CH 2 N(CH 3 ) 2 , -NHCH 2 CH 2 0CH 3 , -OCH 2 CO 2 H, morpholinyl, piperazinyl, N-methyl piperazinyl, piperazinyl-CH 2 CO 2 H, or tetrazolyl; Rz is H, or -CH3; 5 R 3 is -COCH 3 , -CH 2 CF 3 , or -CO 2 H.
13. The method of claim 1, wherein the compound of Formula I administered is selected from the group consisting of N N H HN H HN N N N HO O N-" 0 o 0 O 0 N //N H HN H HN H2 o N ~NH N ~ O O N N H N H H HN N N N N 2 A- oN-0 0 0 N N H HN ~H HN\ / HN \ Nr" N Y" NN N H2 0 0 0 -92 N N HN HO HH H HNN O HN N N H N N N NN N N N N H 0 0 NH HN HN: NN N IN N NN HO O 0 O N OSS H000 HNH H HNN N HO,- 0 N N H 0 00 so -93 O N N N N N HO HO 0 H HN H HN: H NNs N O N NN H 2 N 0 HO 0 O 0 H HN N N HN N S0N N eN HN, O0 N 0 O 0 0 N -- N O N N HO H 2 N 0 O 0 N N N N N HO 'N 0 HO 0 0 0 -94 H HN H N\ N N N N HO 0 N0 0 0 N H HN o N N H 'N - N N HO H 00 0 N N H N H N N ' N N N I N HQ H HO H O 0 0 0 N H NH NH N N NN N -N HO H H 0 0 00 -95 CN H HN H N N N N HO OH O H N N F 3 C CN CN H N H N OH N N NH N 04H 0 H OHj 0~ H (N 0 NO CF3 H N N N NC OH j H NH N CN 0 0 N H O CN NH N CN 0 N H or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof
14. A method of treating osteoporosis, Paget's disease, or other diseases in which bone resorption mediates morbidity including rheumatoid arthritis or other forms of inflammatory 5 arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, or tumor metastasis to - 96 bone in a mammal, comprising administering to the mammal in need of such treatment a therapeutically effective amount of at least one compound of Formula I OyW Z NH X J R 2 5 or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein: R 4 R 4 R 4 Wis HN\ HN\ HN\ HN W is N R4 R4 Ne H 0 wherein each R 4 is independently H, F, Cl, Br, I, OH, OCH 3 , OCH 2 CH 3 , SC( 1 . 4 )alkyl, SOC( 1 . 4 )alkyl, SO 2 C( 1 . 4 )alkyl, -C( 1 . 3 )alkyl, CO 2 Rd, CONReRf, C- CRE, or CN; wherein Rd is H, or -CR 13 )alkyl; Re is H, or -CN 1 3 )alkyl; Ri is H, or -C( 1 . 3 )alkyl; and 15 Rg is H, -CH 2 OH, or -CH 2 CH 2 OH; R 2 is cycloalkyl, spiro-substituted cycloalkenyl, heterocyclyl, spirosubstituted piperidinyl, thiophenyl, dihydrosulfonopyranyl, phenyl, furanyl, tetrahydropyridyl, or dihydropyranyl, any of which may be independently substituted with one or two of each 20 of the following: chloro, fluoro, hydroxy, C( 1 . 3 )alkyl, and C( 1 . 4 )alkyl; Z is H, F, or CH 3 ; J is CH, or N; - 97 R 1 RR R 1 R R RY R X is Rz R Rz R Rz /Rz 0 is R s: 0 ,o Rz Rz Rz Rz wherein R is -C(1. 4 )alkyl, -ORa, -CN, -NA1 2, -SO 2 CH 3 , -COORa, -CO 2 CH 3 , -CH 2 -NA 'A 2 , -CONA 'A 2 , -CH 2 ORa, -OC(. 4 )alkylORa, -NHCH 2 CH 2 CO 2 Ra, 5 -NHCH 2 CH 2 ORa, -NWaCH 2 CH 2 NA 'A 2 , -OC(1. 4 )alkylNA'A 2 , -OCH 2 CO 2 Ra, -CH 2 CO 2 Ra, 12 12 12 -CH 2 CH 2 SO 2 C(1. 4 )alkyl, -SO 2 CH 2 CH 2 NA1A , -SOCH 2 CH 2 NA A2, -SCH 2 CH 2 NA A, -NHSO 2 CH 2 CH 2 NA A 2 phenyl, imidazolyl, thiazolyl, 4H-[1,2,4]oxadiazol-5-onyl, 4H-pyrrolo[2,3-b]pyrazinyl, pyridinyl, [1,3,4]oxadiazolyl, 4H-[1,2,4]triazolyl, tetrazolyl, pyrazolyl, [1,3,5]triazinyl, or [1,3,4]thiadiazolyl; 0 Rz and RY are independently H or -C(1. 4 )alkyl, wherein both Rz may have either syn or anti stereochemistry; alternatively both Rz in a syn relationship may be taken together to form -(CH 2 )n 1 -, where n is 2 or 3; 5 R 3 is H, C(1. 4 )alkyl, C(1. 3 )alkyl-CF 3 , CH 2 CH 2 NH 2 , CH 2 CH 2 ORa, -COCH 3 , -CONH 2 , or -CO2Ra A' is H, -C(1. 4 )alkyl, or CH 2 CH 2 ORa; A2 is H, -C(1. 4 )alkyl, CORa, CH 2 CON(CH 3 ) 2 , -CH 2 CH 2 ORa, -CH 2 CH 2 SC(1. 4 )alkyl, -CH 2 CH 2 SOC(1. 4 )alkyl, or -CH 2 CH 2 SO 2 C(1. 4 )alkyl; 20 alternatively, A' and A 2 may be taken together with their attached nitrogen to form a heterocyclic ring selected from the following: Ra Raa Ra Ra Ra Ra N - 0__/ Rbb N N-- -S N- - O-S NI , Ra 0 -/ , ) Raa Ra Ra Ra Ra Ra N-- S N- - n R N Nzz _/,ad Ra - 98 wherein Ra is H or C( 1 . 4 )alkyl; Raa is H or C( 1 . 4 )alkyl; and Re is H, -C( 1 . 4 )alkyl, -CH 2 CH 2 0CH 2 CH 2 0CH 3 , -CH 2 CO 2 H, 5 -C(O)C( 1 . 4 )alkyl, or -CH 2 C(O)C( 1 . 4 )alkyl.
15. Use of a compound of Formula I as defined in any one of claims 1 to 13, in the manufacture or preparation of a medicament for preventing and treating a disease or disorder selected from the group consisting of inflammation, cancer, cardiovascular disease, diseases with 0 an inflammatory component, pain, metastasis, and autoimmune diseases in a mammal.
16. Use of an effective amount of a compound of Formula I as defined in claim 14 in the manufacture or preparation of a medicament for preventing or treating osteoporosis, Paget's disease, or other diseases in which bone resorption mediates morbidity including rheumatoid arthritis or other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic 5 sarcoma, myeloma, or tumor metastasis to bone in a mammal.
17. A method according to any one of claims 1 to 14; or a use according to claim 15 or claim 16, substantially as herein described with reference to any one of the examples, but excluding comparative examples.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2013200528A AU2013200528B2 (en) | 2006-04-20 | 2013-02-01 | Inhibitors of C-FMS kinase |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/793,667 | 2006-04-20 | ||
AU2007240443A AU2007240443B2 (en) | 2006-04-20 | 2007-04-18 | Inhibitors of c-fms kinase |
AU2013200528A AU2013200528B2 (en) | 2006-04-20 | 2013-02-01 | Inhibitors of C-FMS kinase |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2007240443A Division AU2007240443B2 (en) | 2006-04-20 | 2007-04-18 | Inhibitors of c-fms kinase |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2013200528A1 AU2013200528A1 (en) | 2013-02-21 |
AU2013200528B2 true AU2013200528B2 (en) | 2014-05-08 |
Family
ID=47722603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2013200528A Ceased AU2013200528B2 (en) | 2006-04-20 | 2013-02-01 | Inhibitors of C-FMS kinase |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2013200528B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115317493B (en) * | 2022-06-22 | 2023-04-28 | 中山大学 | Application of boric acid micromolecule compound in preparation of drugs for enhancing curative effect of immune checkpoint inhibitor and treating leukemia |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004096795A2 (en) * | 2003-04-25 | 2004-11-11 | 3-Dimensional Pharmaceuticals, Inc. | C-fms kinase inhibitors |
-
2013
- 2013-02-01 AU AU2013200528A patent/AU2013200528B2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004096795A2 (en) * | 2003-04-25 | 2004-11-11 | 3-Dimensional Pharmaceuticals, Inc. | C-fms kinase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
AU2013200528A1 (en) | 2013-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007240443B2 (en) | Inhibitors of c-fms kinase | |
US9452996B2 (en) | Inhibitors of c-fms kinase | |
AU2013200528B2 (en) | Inhibitors of C-FMS kinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |